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ABSTRACT 
 
Along with increasing research in the field of drug delivery and nanotechnology there is an 
urgent need to improve test tools for efficacy and safety of nanomedicines. In this thesis an 
in vitro model of the inflamed intestinal mucosa was developed which combined with a 
novel silicon nitride based cell culture support advances drug and formulation testing in the 
context of inflammatory bowel disease. The in vitro model consists of an epithelial cell line 
combined with primary macrophages and dendritic cells and stimulated via pro-
inflammatory factors such as interleukin-1β (IL-1ß). The model reflects pathophysiological 
changes observed in vivo e.g. decreased epithelial barrier function, increased production of 
pro-inflammatory cytokines, and increased mucus production. 
The potential as a testing system for (nano)-formulations was demonstrated comparing anti-
inflammatory activity of liposomal budesonide and polymeric nanospheres. Increased 
activity of budesonide nanoparticles which accumulate in the tight junctional region was 
observed. 
In addition, hindered diffusion of particles and macromolecules that caused underestimation 
of transport across standard, polyester based cell culture supports was addressed. The silicon 
nitride based microporous membranes of only 500 nm thickness proposed in this thesis 
provided excellent growth properties while reducing the membrane influence, thus allowing 
the first study on nanoparticle translocation across the intestine in vitro. 
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KURZZUSAMMENFASSUNG 
 
Um die Effizienz und Sicherheit von Nanomedikamenten zu bestimmen müssen in vitro 
Testsysteme angepasst und optimiert werden. In dieser Arbeit wurde ein in vitro Modell der 
entzündeten Darmmukosa und einem neuartigen Silikonnitrid basiertem Zellkultursystem 
entwickelt, mit dem die Testung von Arzneistoffen und Formulierungen zur Therapie 
chronisch entzündlicher Darmerkrankungen erlaubt. 
In einer Ko-Kultur von intestinalen Epithelzellen mit primären Makrophagen und 
dendritischen Zellen, wird über die Zugabe von IL-1ß eine Entzündung ausgelöst. Im 
Modell zeigen sich daraufhin pathophysiologische Veränderungen wie eine Verminderung 
der Barriereeigenschaften und eine verstärkte Produktion von Mukus und Zytokinen.  
Der Einsatz als Testsystem für verschiedene pharmazeutische (Nano)-Formulierungen 
wurde am Beispiel des Budesonid überprüft und wurden miteinander verglichen. Nur die 
Nanopartikel reicherten sich zwischen den Epithelzellen an und hatten die höchste 
antientzündliche Potenz.  
Ein zusätzliches Problem in der in vitro Testung von Nanopartikeln stellen die 
herkömmlichen Zellkultursubstrate auf Basis von Polyestermembranen dar. Auf Grund des 
kleinen Porenradius und der relativen Membrandicke wird die freie Diffusion größerer 
Teilchen über den Filter eingeschränkt. Der Einsatz einer Silikonnitridmembran mit einer 
Dicke von nur 500 nm beschleunigte den Transport der Partikel und erlaubte erstmals die 
Bestimmung relevanter Translokationsdaten über funktionelle Caco-2 Monolayer. 
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1. Introduction 
1.1 Drug discovery and formulation  
Modern drug development consists of a series of processes starting with the identification of 
lead compounds and their pharmacological effects, subsequent study in cell and animal 
models and ending with drug safety, pharmacokinetics and efficacy studies in patients. 
Although drug candidate developments have been optimized through rational drug design 
in recent years, adequate screening processes are needed to narrow down the number of 
potential active pharmaceutical compounds (API) and to refine the formulation through the 
pipeline. 
A variety of obstacles  may present in the translation from in vitro to in vivo (animal testing) 
and from animal testing to preclinical and clinical development which lead to the failure of a 
compound to reach the shelf. One of the main problems in transferring the compound and its 
formulation to in vivo systems is the reliability of the validated simplified in vitro techniques, 
which by design, lack the complexity of the whole tissue, organ or body. 
However, the disadvantages do not overwhelm the advantages as in vitro systems are 
considered (1) more ethical, (2) cheaper, (3) and less time consuming then animal studies, 
and (4) allow testing under clearly defined conditions in a steady environment. This drives 
further developments in modern cell culture and tissue engineering techniques as well as 
progress in molecular biology to provide a wide panel of validated in vitro models with 
increasing complexity. The developed in vitro models mostly developed based on cells from 
human origin thus eliminating problems with species differences.  
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1.2 Epithelial cell culture  
Cell culture based in vitro techniques are particularly important when studying drug 
pharmacokinetics i.e. the process of drug absorption, distribution, metabolism and excretion 
(ADME). Epithelia, the cellular coverings of internal and external body surfaces, can be 
considered as a rate limiting factor in all of these steps [1].  Historically, epithelial cell culture 
models have been proven to be powerful tools in predicting drug bioavailability at the place 
of action and provide mechanistic insight into the interaction between the API and the 
biological barrier. Mass screening of potential APIs and their formulation is thus possible 
due to small scaling and reproducible quality. 
 
Figure 1. Tight junction assembly forming the main barrier in the epithelium. The assembly consists of 
transmembrane protein: occludin, claudins and junctional adhesion molecules (JAMs), and adaptor 
proteins such as zona occludens (ZO1, ZO2 and ZO3) as well as additional proteins. Illustration 
modified from Aktories, K., et al. [2] 
 
 
Internal epithelia are polarized cells and are characterized by the expression of different cell 
contacts: desmosomes and hemi-desmosomes provide adhesion of epithelial cells to each 
other and to the basement membrane respectively and gap junctions are intercellular 
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connection channels. Composed by a strand of several pivotal proteins, with transmembrane 
proteins Claudin and Occludin linked to actin cytoskeleton via ZO-1 to form a beltlike 
network, the tight junctions surround the cells act as the primary gate of the epithelium (Fig. 
1). They serve as a physical barrier to the environment, allowing transport of water and small 
molecules across epithelia but limiting bigger molecules. The assembly, maintenance, and 
disassembly of tight junction protein is regulated by various signaling molecules such as 
protein kinase C, mitogen-activated protein kinases, myosin light chain kinase, and Rho 
GTPases, and influenced by intestinal bacteria and dietary components [3]. 
The tightness of an epithelium can be quantified via the so called transepithelial resistance 
(TEER), i.e. the resistance that the epithelium provides to a current in an electric circuit. The 
higher this resistance value (given as Ω*cm2 i.e. normalized to the surface area), the tighter 
the epithelium and the higher the diffusion barrier is. 
Several transport routes are available depending on the physicochemical properties (size and 
hydrophobicity) of the respective compound. In principal, transcellular (through the cells) 
transport and paracellular (between the cells) transport can be distinguished. Passive 
paracellular transport is mainly limited to hydrophilic molecules sized <300 Da as diffusion 
takes place through the tight junction pores which size varies between 0.5 to 5 nm [4]. 
Moderately lipophilic compounds with logP < 5, molecular weight of up to approximately 
500 Da and up to 5 H-bond donors and 10 H-bond acceptors are transported through the 
cells i.e. they have to diffuse in and out of the phospholipid bilayer of the cell membrane [5]. 
Transcellular transport can either be passive process following a concentration gradient 
between apical and basolateral side of the epithelial barrier, or active transport which 
requires the work against a concentration gradient. Active transport may also enable uptake 
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of bigger or more lipophilic structures mediated by transport proteins embedded in the cell 
membrane. 
In vivo, the basement membrane  anchors down the epithelium to the loose connective tissue 
of the respective organ. In vitro, this  growth support is simulated using porous polyester or 
polycarbonate membranes of ~10 µm thickness which are suspended by a plastic holder in 
standard multi-well cell culture plates. Thereby a two-compartmental system is formed 
which allows nutrient support to the cells from both sides, which gives better approach to 
in vivo condition than the one sided nutrient sustentation in conventional cell culture flasks. 
The epithelial cells can differentiate and polarize in this setup, as confirmed by a hindered 
lateral diffusion across the cell membrane and the distinct expression of microstructures and 
membrane proteins on the apical lumen site and on the basolateral tissue site. Transport 
processes of ions, nutrients and drug compounds can easily be studied in this setup as it is 
assumed that the epithelial layer provides the main barrier for diffusion of small molecular 
compounds while the resistance of the porous membrane is negligible. However, not in all 
cases the filter support is completely inert; highly lipophilic substances, proteins or particles 
could adsorb to the material and might clog the pores.  
 
1.3 In vitro models of the intestinal mucosa 
Out of all drug delivery strategies, oral application is the most frequently used with more 
than 40% of all APIs being applied as tablets [6]. Oral delivery of tablets is both price efficient 
in production and convenient for the patient with good compliance to therapy. Formulated 
to withstand the low pH of gastric tract, the drug absorption mostly takes place in the small 
intestine which is substructured by the formation of villi and microvilli greatly increasing the 
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surface area available for absorption. With a huge interface of approximately 250m2, small 
intestinal mucosa offers a huge absorption surface area. They are mainly comprised of 
enterocytes covering most of the surface, but also consist of other cell types such as mucus-
producing goblet cells or M-cells, specialized in the uptake of particulate structures and 
potentially harmful microorganism and subsequent presentation to the immune system. 
Thus to simulate simple absorption, enterocyte cell lines are used. A number of cell culture 
models for the intestinal epithelium are available, but only few develop functional tight 
junctions that are needed  for pharmacokinetic studies (such as Caco-2 and T84) [7]. 
The in vitro model developed in our study is based on the most common model for epithelial 
barrier, Caco-2 cell line. Caco-2 cells were first isolated from human colon adenocarcinoma of 
a 77 year-old male Caucasian in the 1970s. When grown on permeable membrane supports, 
the proliferation stop after confluence and the cells differentiate to small intestinal 
enterocyte-like cells forming polarized, fully differentiated monolayers. Phenotypical 
characteristics include microvilli on the apical side, the formation of functional tight 
junctions, and the expression of a wide range of metabolic enzymes (e.g. small intestinal 
hydrolases, including sucrase-isomaltase, lactase, aminopeptidases) and of transport proteins 
on the apical (e.g. P-gp, MRP-2, BCRP) and basolateral (e.g. MRP-1, PepT1) surfaces [8]. A 
comparative study on 20 different intestinal cell lines, found Caco-2 to have the highest 
correlation to the in vivo enterocyte phenotype e.g. showing the highest enrichment factor of 
brush boarder-associated hydrolases enzyme activity [9]. 
Despite having higher TEER values compared to the in vivo small intestinal epithelium [10] 
and deficits in the expression of certain enzymes (e.g. CYP3A4) the permeability of a wide 
range of APIs across Caco-2 cell monolayers was found to correlate to in vivo permeability 
data. Thus Caco-2 is one of the chosen cell line to predict permeability and subsequently 
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bioavailability of drug candidates in the context of the Biopharmaceutical Classification 
System (BCS) and the biowaiver guideline of the Food and Drugs Administration (FDA) [11]. 
Additionally, Caco-2 is also a well established model to perform in-depth mechanistic and 
absorption studies, to study the role of transporters and potential transporter-
mediated drug-drug interactions.  
 
1.4 Advanced in vitro models techniques 
Although the Caco-2 model can be considered the gold standard for epithelial in vitro models 
in the context of drug absorption and bioavailability studies, it faces some limitations if other 
questions are to be addressed, e.g. the prediction of drug toxicity and efficiency at an organ 
level. The interplay between different cell types such as epithelial cells and immune cells or 
between cells and the extracellular matrix is essential for these kinds of questions and is not 
mirrored in the simplified one dimensional monoculture models. Therefore, in recent years 
several approaches have tried to improve the predictive power by enhancing the geometrical 
and cellular complexity as well as the quality of cell culture techniques, relying less on cell 
lines of cancerous origin and trying to address specific pathophysiological conditions.  
 
1.4.1 Co-culture of multiple cell types 
Depending on the tissue to be mimicked, the cell types that are used vary from combination 
of epithelial cells and immune cells in the intestine and lung, or endothelial cells and 
immune cells in vascular models to co-cultures of endothelial cells with neuronal cells at the 
blood brain barrier.  
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At the intestinal barrier, several groups have tried to compensate for the low mucus 
production in Caco-2 cells by adding goblet like cells. Combining Caco-2 with HT-29 at the 
correct seeding rate, the system develops good barrier properties which cannot be achieved 
in HT-29 monocultures but shows significantly raised mucus levels. The benefit of these 
models for permeability studies is limited, as in vitro-in vivo correlation for small molecular 
compounds was not greatly improved compared to Caco-2 monoculture.  However, they are 
highly relevant for drug formulation with specific mucoadhesive targeting (e.g. chitosan, 
eudragit analogues, etc.) [12, 13] or when studying transport of macromolecular structure 
and particles.  
Other systems increase the immunocompetency of the intestinal cell culture model. In a 
pharmaceutical context, in particular M cell models have been investigated by co-culturing 
Caco-2 cells with Raji B cells. The early model by des Rieux et al. [14] has been improved 
over the years by changing the orientation of the epithelial cells within the compartmental 
setup,  and was found to have 50-fold higher transport rate of nanoparticles compared with 
conventional monoculture or more than 15-fold of previous M-cell model.  This model has 
been used widely in the research for permeability and antigen uptake by M-cells. However, a 
comparison study with in vivo condition is urgently needed to define the relevant model, as 
depending on the setup, the model gave high variation in permeability. 
In a more medical context,  Spottl et al. co-cultured HT-29, primary fibroblasts and primary 
monocytes and discovered the alternative differentiation of the co-cultured macrophages 
towards M2 phenotype [15], producing less CD14, CD11b , CD80, and CD86 expression, a 
condition similar to the intestinal macrophages. The model mostly focused on the interplay 
of the different cell types and the secretion factor driven differentiation of the immune cells 
and less for characterization in regards of intestinal barrier properties. 
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Table 1. List of advanced 3D in vitro models of biological barriers for specific characterization and 
disease study. 
Organ Cells Studied system Reference 
Intestine  
 
1. Caco-2 
2. Raji B line 
Human intestinal follicle-
associated epithelium (FAE) 
and M-cells for nanoparticle 
transport study  
[14] 
1. Exosomes harvested 
from high MHC class II 
expressing T-84 cells 
2. HLA-DR4 (EBV-
transformed human B-
cell line) or DCs 
Human epithelial exosomes 
in antigen presentation 
 
[16] 
1. primary enteric 
neuronal tissue 
2. HT-29 
Model of innervated mucosal 
barrier 
(Hirschsprung’s disease) 
[17] 
1. Submucosa from 
colon cancer patients 
2. HT-29- Cl.16E 
Colon carcinoma model [18] 
1. Apc+/+ or Apc+/min 
mouse colon epithelial 
cells 
2. large intestine intra-
epithelial lymph (LI-IEL) 
also from mouse 
Mouse colon 
 
[19] 
1. Caco-2 
2. RAW264.7 cells 
Assessment of anti-
inflammatory effect from 
food factors in the intestine 
[20] 
1. Caco-2 clone TC7 
2.  HT-29-MTX (goblet-
like cells) 
Model for internal 
absorption prediction in 
human intestine 
[21] 
1. Caco-2 
2. Leukocyte 
3. E.coli, L.johnsonii, L. 
sakei 
Study of bacterial response 
of  IEC in regards of 
interaction with 
immunocompetent cells. 
[22] 
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Organ Cells Studied system Reference 
Lung 
 
 
1. A549 (epithelial cells) 
2. airway macrophages 
(AM) from PBMC 
3. dendritic cells (DC) 
derived from PBMC 
Human airway barrier 
to study interaction with 
particles 
[23] 
Blood-
brain-
barrier 
 
1. primary rat brain 
endothelial cells (RBEC) 
2. primary astrocytes 
Rat BBB model for molecular 
analysis of efflux 
transporters 
[24] 
1. Brain capillaries from 
calf 
2. astrocytes from 
newborn rats 
In vitro model of BBB for 
physiological, 
pharmacological and 
pathophysiological study 
[25] 
Vascular 
endothelial 
1. HUVEC (human 
umbilical vein 
endothelial cells) 
2. U937 (monocyte cell 
line) 
Arthrosclerosis model [26] 
Dental 1. HeLa 
2. U937 differentiated to 
adherent macrophage-
like cells 
Chronic periodontal tissue 
destruction 
[27] 
Tyroid 1. Human thyrocytes 
2. Monocytes 
Thyroid epithelial barrier [28] 
Spheroids 3-d cell spheroids 
generation by RWV 
bioreactor. 
Study of infectious diseases [29] 
Eyes SV-40 immortalized 
human endothelial and 
epithelial cells and 
native stromal 
cells(fibroblasts) 
Cornea in vitro model [30] 
The significance of dendritic cells in nanoparticle uptake has been shown in an in vitro model 
of at blood air barrier developed by the Rothen-Rutishauser group [23]. The model combines 
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A549 or primary lung epithelial cells co-cultured with blood derived macrophages on the 
apical side and dendritic cells on  the basolateral side of the filter insert. Nanoparticles were 
found to be taken up by wandering alveolar macrophages and transferred to dendritic cells 
beneath the epithelial layer without disrupting the epithelial barrier, demonstrating direct 
interaction of different cell types in the recognition and presentation of particles and foreign 
objects to the immune system in vivo. 
 
1.4.2 Disease relevant in vitro models 
A certain level of complexity is also needed for mimicking pathophysiological conditions, in 
particular to mirror inflammatory or autoimmune conditions. While the inflammation 
process itself is quite straightforward and can be simulated by adding the source of 
inflammation to the model, the process in autoimmune diseases is more complex.  
Their pathogenesis is based on signaling between different cell types i.e. tissue cells, adaptive 
and innate immune cells and leads to the immune system attacking the body’s own tissues, 
subsequently resulting in increased inflammation.  
Table 2 lists the infection models currently available in the research with a clear focus on 
autoimmune conditions can be observed with models for inflammatory bowel disease being 
most prominent. The models were utilized for specific aims either for observation of the 
effect of external stimuli on the inflamed model or to analyze the basic mechanism of the 
inflammation in this specific disease. 
For inflammatory bowel disease, most in vitro models involved epithelial cells and immune 
cells. This can be developed by co-culturing of Caco-2 or primary colonic crypt cells and 
either primary monocytes from healthy or IBD patients or activated THP-1 cells (Table 2) [31] 
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[32]. The critic point for the model is the sample-to-sample variability for cells taken from 
IBD patients for screening process, although this may give a better approximation for a 
personalized drug therapy. In some cases intestinal microorganism are added to induce 
inflammation sometimes with addition of cytokine to enhance the inflammatory response. 
Phorbol 12-myristate 13-acetate (PMA)-activated THP-1 cells are widely used as alternative 
to primary macrophages due to its simplicity and morphological similarities. However, 
research findings showed relatively low correlation coefficient of transcripted genes in 
THP-1 and primary cell types. Therefore data generated from activated THP-1 cells should 
only be interpreted cautiously and better approach is needed to model immune cells in 
activated state. 
 
 
Table 2. List of cocultures as in vitro models of inflammatory diseases 
Disease Cells Studied system Reference 
Inflammatory 
bowel disease 
1. Caco-2 or primary colonic 
crypts cells 
2. PBMC and monocyte-
depleted T cells from healthy 
and IBD patients 
 
Cytokine analysis in 
IBD model 
[31] 
1. Caco-2 
2. activated THP-1 
(monocyte cell line) 
 
Co-culture system  for 
epithelial cell survival 
study in IBD 
[32] 
1. HT-29/MTX or Caco-2 
(HTB 38) 
2. PBMC from healthy donor 
or IBD patients 
3. B. Vulgates or E.coli 
 
Effect of non-
pathogenic gram (-) 
bacteria to pro-
inflammatory gene 
expression in IBD 
[33] 
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Disease Cells Studied system Reference 
Inflammatory 
bowel disease 
1. monocytes from PBMC 
2. primary intestinal 
fibroblasts 
3. HT-29 
 
Cell-cell interaction in 
intestinal mucosa 
microenvironment 
 
[15] 
1. T84 
2. CCD-18Co (myofibroblast) 
3. Lamina propria 
mononuclear cells (LPMC) 
 
CD model  
 
 
[34] 
Asthma 
 
1. BEAS-2B (bronchial epithel 
cell line) or primary 
bronchial epithelial cells 
(BEC) from asthmatic 
patients 
2. monocyte-derived DCs 
(MDDCs) 
 
Asthmatic bronchial 
epithelium activated 
by the an allergene 
[35] 
Arthritis 1. Fibroblast-like synoviocyte 
or dermal fibroblasts 
2. U937 cells 
 
Cytokine analysis in 
inflamed synovium 
[36] 
1. bovine cartilage discs 
2. human synovial fibroblast 
Degradation of 
cartilage matrix 
components and 
synovial fibroblast 
activation 
[37] 
Tuberculosis 
 
Human PBMC or J744 Invasion and 
intracellular 
replication of 
Mycobacterium 
tuberculosis 
[38] 
1. NR8383 Cells 
2. Mycobacterium 
tuberculosis 
Chronic Infection of 
Mycobacterium 
Tuberculosis 
[39] 
Vascular 
endothelial 
Human umbilical Veins Leukocyte adhesion to 
inflammatory  sites 
[40] 
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1.5  Inflammatory Bowel Disease  
Crohn’s disease (CD) and ulcerative colitis (UC) are the most prevalent and commonly 
studied forms of inflammatory bowel disease (IBD), a group of chronic idiopathic 
inflammatory conditions of the gastrointestinal tract [41, 42]. In the US, more than 1.4 million 
people suffer from IBD and it is one of the highest causes of gastrointestinal morbidity. UC 
and CD differ in the intestinal areas and segments of the mucosa affected but present similar 
symptoms for example diarrhea, bloody stool, weight loss, abdominal pain, fatigue and 
fever. The pathogenesis of IBD is still not completely understood but an exaggerated 
immune response to the commensal intestinal microbial flora is assumed, leading to a 
weakening of the intestinal barrier function and further influx of pathogens. Genetic 
predisposition and environmental factor such as food intake and environmental pollutants 
also contribute to the disease. Still incurable, the current treatment schemes for IBD include 
non-specific anti-inflammatories and immunosuppressives to induce and maintain 
remission. Still, 60 to 80% of CD patients require surgery at one point in their life, while only 
20% of UC patients need surgical intervention. In anti-inflammatory and immunosuppresive 
therapy both systemic and local colon targeted dosage forms are used. However, targeted 
drug delivery with conventional system has proven to be a challenge in IBD, as drug 
retention time in the gastrointestinal tract is significantly reduced due to diarrhea and the 
intravenous approach tends to have low bioavailability at the actual site of action combined 
with strong adverse effects and systemic toxicity. 
Nanomedicines may enhance therapeutic options in IBD.  Nanoparticles, by their size alone, 
were shown to accumulate in affected regions of the intestine in a TNBS induced rat model 
of colitis [43]. In the inflamed state, a reorganization of the tight junctions can be observed, 
leading to a leakier epithelium. Furthermore, immune cells such as neutrophils invade the 
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inflamed tissues in high numbers. Comparable to the Enhanced Permeation and Retention 
(EPR) effect observed at the leaky tumor vasculature, it is thus possible to passively target 
inflamed intestinal areas with nanomedicines, leading to a formation of local drug depots 
and reducing required doses as well as drug associated adverse effects.  
Drug and formulation testing in IBD therapy so far has mostly been conducted in chemically 
induced rodent models of colitis. DSS (Dextran Sulfate Sodium) applied via the drinking 
water and TNBS (2,4,6-trinitrobenzenesulfonic acid) given intrarectally are commonly used 
to induce severe epithelial damage and inflammation with only low involvement of T cells 
and of the adaptive immune system. While in general the application of the chemical 
irritants induces an acute epithelial inflammation, repeated cycles of induction and recovery 
periods can also induce a chronic in vivo model. Although more relevant to the 
pathophysiology of the disease in humans, the chronic models are rarely used in drug or 
formulation testing as the length of the induction period as well as the loss of mice during 
that time make the test system more variable and unpredictable. Yet, the predictive power of 
the chemically induced colitis model is limited to a certain extent and can lead to failures to 
clinically translate experimental findings. 
Recently, genetically modified mice such as IL-10 knockout mice have been established as 
IBD animal model and give better approach in chronic inflammatory disease. Species 
differences and differences in pathogenesis hinder drug and formulation testing in this 
regard. Recently, genetically modified mice s.a. IL-10 knockout mice have been established 
as IBD animal model as they develop a chronic enterocolitis due to an aberrant immune 
response to normal enteric antigens. Despite of giving a more relevant model, the genetically 
modified mice still lost its edge to the more popular and easy to maintain chemically induced 
animal model due to the high cost and sensitivity of the mice. 
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1.6 Nanocarrier systems in drug delivery 
The medical application of nanomedicine has been gaining popularity in recent years. 
Defined as carrier systems in the nanosize range (preferably <100 nm), nanocarriers has been 
widely studied for drug or contrast agent loading vehicle. The size of carriers and its 
modification with PEG molecules has been also shown to increase the circulation time in the 
body, as they may escape the absorption and clearance by the mononuclear phagocyte 
system, therefore increasing the availability and potential accumulation in the targeted area. 
Some carriers can be also used as a trojan horse to shield the hydophobicity of drug 
compounds and increased the bioavailability. Additionally, targeting moiety can be added to 
increase the active targeting of the drug to the site of action to enable specific targeting and 
sustained release of the loaded drugs and therefore reducing the side effects. The advantage 
of higher surface area is not only useful for moiety targeting but also for various imaging 
modalities. Some newer approaches in the development of imaging modalities targeted for 
theranostic (therapy and diagnostic) function. In this approach, drug and imaging probe 
loaded to nanoparticles are targeted to certain receptor to facilitate simultaneous targeted 
drug therapy and monitoring the therapy responses. 
In inflammatory diseases, the vasculature and epithelial barriers seems to be leakier due to 
the reorganization of the tight junction, causing the Enhaced Permeation and Retention 
(EPR) effect similar to the tumor environment. This fact has been used previously for drug 
delivery in cancer therapeutics, as the leaky barrier may allow smaller nanovehicle to breach 
the barrier and accumulate in the cancer environment, letting them to release the therapeutic 
agents specifically in the area. In IBD, the targeting and prolonged circulation time results in 
the accumulation of the drugs at the inflamed sites in higher concentration than in the 
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healthy tissue. This may reduce the adverse effect and improve the strategy of optimized 
longer lasting medication with less side effects. 
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1.7 Aims of the thesis 
With the in vivo models being ethically questionable, time consuming and of limited 
predictive power for drug and formulation testing, a disease relevant in vitro model can help 
overcome this bottleneck in the development pipeline of new IBD therapeutics. However, the 
available in vitro models so far are not suited for drug testing at the inflamed intestinal 
barrier as they either lack the pathophysiological background and complexity or were 
developed for a mechanistic study of disease origin failing to optimize the system for 
pharmacokinetic investigations. Thus, the aim of this thesis was to bridge this gap 
developing an in vitro model of the inflamed intestinal mucosa that in the healthy state 
demonstrates good epithelial barrier properties and then could be triggered to an inflamed 
state mirroring pathological symptoms of the inflamed intestine. 
In the setting up of the system candidate epithelial cells and pro-inflammatory reagents were 
screened and a co-culture model incorporating primary blood derived immune cells was 
established. The model was characterized in the non-inflamed as well as in the inflamed state 
for epithelial barrier function and disease markers. 
In the testing of the predictive potential of the model a liposomal and particulate formulation 
of the glucocorticoid budesonide were applied and recovery of epithelial barrier function 
and reduction of inflammation were monitored. Not only was it possible to treat the model 
but also mechanistic conclusions on the interaction of nanomedicines with the inflamed 
epithelial barrier could be drawn.  In the context of nanomedicines it also became necessary 
to optimize cell culture tools for epithelial in vitro models to improve translocation studies. 
Using ultrathin porous silicon nitride membranes a novel cell culture system was established 
that can be combined with the inflamed co-culture model in future studies.  
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2. A 3-dimensional co-culture of enterocytes, macrophages and 
dendritic cells to model the inflamed intestinal mucosa in vitro 
 
 
 
 
 
 
Parts of this chapter have been published in: 
Fransisca Leonard, Eva-Maria Collnot, Claus-Michael Lehr. A 3-dimensional co-culture of 
enterocytes, macrophages and dendritic cells to model the inflamed intestinal mucosa in 
vitro, Mol Pharm 2010 Dec 6;7(6):2103-19. Epub 2010 Nov 1. 
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2.1 Abstract 
While epithelial cell culture models (e.g. Caco-2 cell line) are widely used to assess the 
absorption of drug molecules across the healthy intestinal mucosa, there are no suitable in 
vitro models of the intestinal barrier in the state of inflammation. Thus development of novel 
drugs and formulations for the treatment of inflammatory bowel disease is largely bound to 
animal models. We here report on the development of a complex in vitro model of the 
inflamed intestinal mucosa, starting with the selection of suitable enterocyte cell line and 
pro-inflammatory stimulus and progressing to the setup and characterization of a three 
dimensional co-culture of human intestinal epithelial cells and immunocompetent 
macrophages and dendritic cells. 
In the 3D setup, controlled inflammation can be induced allowing to mimicking 
pathophysiological changes occurring in vivo in the inflamed intestine. Different 
combinations of pro-inflammatory stimuli (lipopolysaccharides from E. coli and S. 
typhimurium, IL-1ß, IFN-γ) and intestinal epithelial cell lines (Caco-2, HT-29, T84) were 
evaluated and only Caco-2 cells were responsive to stimulation, with IL-1ß being the 
strongest stimulator. Caco-2 cells responded to the pro-inflammatory stimulus with a 
moderate up-regulation of pro-inflammatory markers and a slight, but significant decrease 
(20%) of transelectrical epithelial resistance (TEER) indicating changes in the epithelial 
barrier properties. Setting up the co-culture model, macrophages and dendritic cells derived 
from periphery blood monocytes were embedded in a collagen layer on Transwell filter 
insert and Caco-2 cells were seeded atop.  
Even in the presence of immunocompetent cells Caco-2 cells formed a tight monolayer. 
Addition of IL-1ß increased inflammatory cytokine response more strongly compared to 
Caco-2 single culture and stimulated immunocompetent cells proved to be highly active in 
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sampling apically applied nanoparticles. Thus the 3D co-culture provides additional 
complexity and information compared to the stimulated single cell model.  The co-culture 
system may serve as a valuable tool for developing drugs and formulations for the treatment 
of inflammatory bowel diseases, as well as for studying the interaction of xenobiotics and 
nanoparticles with the intestinal epithelial barrier in the state of inflammation.  
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2.2 Introduction 
Inflammatory bowel diseases (IBD), such as Crohn’s disease or colitis, have been postulated 
as being associated with both defects in the intestinal barrier and an impaired immune 
function. Genetic predispositions such as mutations in the NOD2 gene, as well as different 
environmental factors may also have contributed [44]. IBDs have been characterized by an 
exaggerated pro-inflammatory immune response to the commensal intestinal microbial flora. 
Studies have demonstrated also that this aberrant inflammation leads to an increased 
permeability of the intestinal epithelial barrier, allowing toxins and microbes to reach the 
underlying tissues [45]. Several studies reported for both affected and unaffected areas 
alterations in the mucosal architecture, such as transcellular bridge formation in epithelial 
cells and goblet cell hyperplasia or hypertrophy or both [46]. 
While most IBDs  have so far been considered as incurable, therapeutic measures are 
directed to treat the symptoms by anti-inflammatory drugs and to prolong the remission by 
various immunomodulators especially corticosteroids [44]. Besides several approaches to 
optimize drug delivery by colon targeted dosage forms [47]efficient drug delivery in IBD is 
still hampered by diarrhea, a prominent symptom of the disease. Diarrhea decreases the 
drug carrier residence time thereby also shortening the time window for drug release and 
absorption [48]. Novel drug carriers have been designed to overcome this problem by 
decreasing the particle size. Several microparticulates have been shown to be successful in 
experimental treatment of IBD [49, 50]. In a rat model of IBD nanoparticles showed an even 
more pronounced retention effect in inflamed, mucus-rich areas of the intestine in 
comparison to microparticles, and prolonged anti-inflammatory action [43]. 
To further improve drug delivery in IBD a better understanding of the disposition of drugs 
and (nano)particulate delivery systems in the targeted tissue is essential. In conventional 
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ADME screening, cell lines such as Caco-2 are widely accepted as a model of the normal, 
healthy intestinal mucosa. However, models which consist only of enterocytes cannot mimic 
the complex interactions with other cells, in particular of the immune system. Such 
interactions however may be of utmost importance for the epithelial barrier function as well 
as for the uptake and translocation of (nano)particles in the state of inflammation. 
In preclinical studies, animal models are mostly preferred. However, apart from its intrinsic 
complexity and ethical controversies, the main problems of animal model lies in the species 
differences compared to man, which often causes misleading results [51]. Chemically 
induced IBD by sulfonic acid derivatives TNBS and DSS in mice has been widely used in 
experiments. While these models show some characteristic histological and pathological 
changes, the reproducibility is difficult since the induced inflammatory effects depend on the 
dose, species and strain of the animal used. High dose of TNBS is needed to induce the 
colitis, which normally leads to high mortality rate of tested animals and impedes the 
pharmacological studies. Moreover, dimension differences of test animals here cannot be 
neglected as the length of small intestine in mice is less than 50 cm [52]. The induced colitis 
in mice may impact the whole intestine compared to only patches of inflamed regions in 
humans which have a small intestine length of about 3 to 4 m [53]. 
The crucial disadvantage of the chemically induced animal models is their limited relevance 
for human IBD as shown by the lack of responsiveness to corticosteroids and 5-ASA therapy 
[54]. Furthermore, these models simulate more an acute tissue injury of intestinal epithelial 
and are therefore less representative of an immune response-directed chronic inflammation. 
Other models such as transgenic or knock out genes based models have significantly 
increased in numbers recently. They are suitable to observe the pathological changes in 
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organism with disrupted genes, but their specificity makes their uses for common anti-
inflammatory substances therapy testing in general inflammation of IBD questionable.  
Intestinal epithelium plays the central role in inflammatory response and so far several 
enterocyte cells such as HT-29, T-84 and Caco-2 have been widely used to study intestinal 
epithelial barrier function [55]. These cells however, are cancer derived and not supposed to 
reflect the pathophysiological changes in the state of inflammation. Therefore, the objective 
of this study was to expand on the cell characteristic and establish a model of intestinal 
mucosa in the state of inflammation. This was achieved by stimulating intestinal epithelial 
cells with pro-inflammatory compounds such as LPS from intestinal micro flora and several 
chemokines or cytokines such as IL-1ß, TNF-α and IFN-γ.  
Another point to be taken in consideration is the complexity of the tissue in vivo. Immune 
cells are particularly important in the pathogenesis of inflammatory bowel disease since they 
are highly dysregulated and mistakenly take up harmless non-pathogenic intestinal flora, 
processing them as an antigen [56]: Naïve dendritic cells are activated by inflammatory 
cytokines upon capturing antigen through pinocytosis and phagocytosis. They then carry the 
antigens and present them to naïve T-lymphocytes located in the lymph nodes, where the 
antibodies against the antigens are formed. Macrophages are able to eat up some microbes or 
infected/cancerous cells. After processing they also present the antigen to helper T-cells, 
thus activating adaptive immune response.  
We herein describe the development of a new three-dimensional in vitro model from starting 
with the selection of an adequate enterocyte cell line and inducer of inflammation and 
progressing to the setup and characterization of a more complex co-culture model. The co-
culture encompasses human intestinal epithelial cells and primary, blood derived 
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macrophages and dendritic cells and can be utilized as a stepping stone between the classical 
in vitro single cell culture testing and in vivo testing. The model was characterized with 
regards to release of pro-inflammatory marker IL-8, re-organization of tight junction proteins 
and recovery after removal of the pyrogenic compounds. The effects were evaluated by 
histology, immunohistochemistry and TEER measurement as well as by changes in 
expression and translation of key genes in the inflammatory cascade. Furthermore the barrier 
properties of the novel model for the transport of marker compound fluorescein sodium and 
the interaction with drug-free polymeric nanoparticles was evaluated. 
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2.3 Material & Methods 
2.3.1 Materials 
Human colon adenocarcinoma cell line Caco-2 clone C2Bbe1, HT-29 and T84 was obtained 
from American Type Culture Collection (Rockville, MD). Dulbecco’s modified Eagle’s 
medium (DMEM) was purchased from Gibco (Carlsbad, CA), Fetal calf serum and non-
essential amino acids were purchased from PAA (Pasching, Austria). Trypsin/EDTA was 
obtained from Sigma (Steinheim, Germany). Plastic dishes, plates were obtained from 
Greiner Bio-One, Transwell inserts with pore size 0.4 µm were purchased from Corning 
Incorporated (Acton, MA, USA). IL-1ß, GM-CSF and IL-4 were purchased from R&D 
Systems (Minneapolis, USA) and Lipopolysaccharide(LPS) originated from both E.coli and 
S.typhimurium were obtained from Sigma (Steinheim, Germany). Ficoll Paque plus for 
PBMC isolation was obtained from GE Healthcare (Uppsala, Sweden) and human serum 
from Invitrogen (Wisconsin, USA). 4′,6-Diamidino-2-phenylindol, Fluorescein sodium salt 
(FluNa) and organic solvents were acquired from Sigma (Steinheim, Germany). Rabbit anti-
ZO-1 antibody, rabbit anti-Claudin-1 and mouse anti Occludin antibodies were obtained 
from Zymed Laboratories Inc (San Francisco, CA) and fluorescence coupled goat-anti rabbit 
and anti-mouse secondary antibody was purchased from BD Biosciences (Heidelberg, 
Germany). R-PE-coupled CD14 antibody for FACS analysis was purchased from Chemicon 
Internationals (Temecula, California 92590, USA) and FITC-coupled CD1a was purchased 
from BD Biosciences (Heidelberg, Germany). CBA human IL-8 Flex Set was also purchased 
from BD Biosciences (Heidelberg, Germany). RNeasy Mini Kit, QuantiTect Reverse 
Transcriptase and QuantiTect Probe Kit were from Qiagen (Hilden, Germany). Alcian blue 
was obtained from Sigma (Steinheim, Germany). Fluorescein- coupled Fluoresbrite 
carboxylate microspheres with size ranging from 50 to 500 nm were purchased from 
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Polysciences, Inc (Pennsylvania, USA). Purecol collagen was obtained from Advanced 
Biomatrix (Tucson, Arizona, USA). Veronal buffer (pH 8.5) for acid phosphatase staining was 
obtained from Morphisto (Frankfurt, Germany). All chemicals used in this study were of 
analytical grades. 
 
2.3.2 Cell culture 
Caco-2 clone C2Bbe1 (passage 65-78) were grown in a culture medium composed of DMEM, 
10% FCS and 1% non-essential amino acid and maintained at 37°C in a 5% CO2 and 95% 
humidity environment. HT-29 cells were grown in McCoy’s medium with 10%FCS addition 
while T84 cells were grown in DMEM/F12 medium with 5% FCS supplement and 
maintained in similar condition as Caco-2. The medium was changed every other day and 
the cells were sub cultured every week at a split ratio of 1 to 20 by treatment with 0.1% 
trypsin and 0.02% EDTA. 
 
2.3.3 Cell stimulation, isolation of RNA and reverse transcription 
Caco-2 cells were cultivated in 6-well plate at a seeding density of 1.2 x 105 cells/cm2. Total 
RNA was extracted from Caco-2 cells using Qiagen RNeasy Mini Kit after stimulation with 
varying concentration of LPS and IL-1ß and exposed for 2 to 24 hours. The double stranded 
cDNA was synthesized from 1 µg mRNA using the Qiagen QuantiTect Reverse Transcriptase 
Kit and the product was used for further analysis with real-time PCR.  
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2.3.4 Quantification of pro-inflammatory gene expression with real-time PCR 
PCR analysis was performed for 35 cycles (95°C for 12 seconds, 60°C for 45 seconds) with 75 
ng of the synthesized cDNA, each 0,1 µl of 50 µM primers and 12,5 µM fluorescent probe 
using QuantiTect PCR Probe Kit. Sequences of primer pairs and probes are shown in table 3. 
An internal standard was included for each set of RNA samples analysed and standard 
curves were calculated for the quantification. 
 
Table 3. Primer sequences for mRNA quantification by realtime PCR. All sequences were 5’ ->3’. 
FAM= Fluorecein and BHQ1= Black Hole Quencher 1. 
Gene Sequences Product (bp) 
ß-actin Sense:  TGC GTG ACA TTA AGG AGA AG 
A:         GTC AGG CAG CTC GTA GCT CT 
Probe:  FAM-CAC GGC TGC TTC CAG CTC CTC-BHQ1 
107 
TNFα Sense:  CTC CAC CCA TGT GCT CCT CA 
A:         CTC TGG CAG GGG CTC TTG AT 
Probe:  FAM-CAC CAT CAG CCG CAT CGC CGT CTC-BHQ1 
99 
IL-8 Sense:  TGC CAG TGA AAC TTC AAG CA 
A:         ATT GCA TCT GGC AAC CCT AC 
Probe:  FAM-TCA ACA CTT CAT GTA TTG TGT GGG TCT G-BHQ1 
78 
 
2.3.5 Protein expression assessment with FACS-based CBA Flex kit 
The initial study to compare the effect of various pro-inflammatory compounds on the IL-8 
release was conducted with Caco-2. Caco-2 cells were cultured in 96-well plate at a seeding 
density of 2 x 104 cells/well. The assay was conducted after the cells formed a monolayer. 
3D in vitro model of inflamed colonic mucosa  
 
29 
 
Cells were stimulated with various concentration of either LPS or IL-1ß. 50 µl of the 
supernatant was used for IL-8 protein expression measurement. 
IL-8 release was also measured in the established inflamed co-culture and compared with the 
releasefrom stimulated and non-stimulated Caco-2 monoculture. For this purpose , Caco-2 
cells with seeding density of 6x104 cells/filter were grown on collagen coated Transwell 
inserts, with macrophages and dendritic cells embedded in the collagen for the co-culture 
setup. The assay was conducted after 21 days of cultivation. 10 ng/ml IL-1ß were added to 
the apical side to induce the inflammation and 50 µl of the apical and basolateral fluid were 
sampled after 24 h.  IL-8 protein expression was measured by CBA Flex Set for IL-8 
according to the manufacturer protocol.  
 
2.3.6 Transepithelial electrical resistance and paracellular permeability  
For Transepithelial electrical resistance (TEER) measurements, the cells were grown in 
Transwell inserts at a seeding density of 6x104 cells/cm2. The cells formed fully differentiated 
monolayer after 21 days in culture. The integrity of cell monolayer was monitored by TEER 
measurement with Epithelial Voltohmmeter (World Precision Instruments, Sarasota, US). 
Monolayers with TEER value higher than 400 Ω*cm2 were used for the experiments. 
 
2.3.7 Immunostaining of tight junctional protein 
Tight junction protein ZO-1, Occludin and Claudin-1 were stained with immunofluorescent 
antibodies. Caco-2 cells were seeded in Transwell filters as previously described. The cells 
were fixed with 100% ethanol at 4°C for 30 minutes and then incubated with either rabbit-
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anti human ZO-1, mouse-anti human Occludin or rabbit-anti human Claudin-1 antibody 
(suspended in PBS + 1% BSA solution) for 1 hour followed by incubation with secondary 
antibody for 30 minutes and DAPI staining for 10 minutes. Fluorosafe was used to mount the 
filters onto cover slips. A Zeiss LSM 510 confocal microscope with the software LSM510 
package was used for capturing fluorescent images of the immunostainings. Images were 
captured with z-stack to record three-dimensional dataset. This was done by random 
sampling to represents the general condition of the model. Volocity (Improvisions, 
Lexington, MA, USA) imaging software was used to reconstruct 3D images from stack 
datasets using Mackintosh computer. 
 
2.3.8 Permeability of fluorescein on the Caco-2 cell monolayer 
Tight Caco-2 moonolayer obtained 21 days after seeding was used for fluorescein transport 
experiment.Transport was assessed in both absorptive (apical  basolateral) and secretory 
(basolateral  apical) directions.  1µg/ml FluNa was dissolved in transport buffer consisting 
of DMEM without phenol red and 10% FCS. Cell monolayers on Transwell filters were 
rinsed gently twice and pre-incubated in transport buffer for one hour at 37°C and 5% CO2. 
FluNa was added to the donor compartment and transport buffer was added to the acceptor 
compartment. Cell monolayers were agigated throughout the experiments with orbital 
shaker from IKA Werke GmbH & Co KG (Staufen, Germany). At different time points 50 µl 
samples were taken from the receiver compartment and the volume lost during sampling 
was replaced with fresh buffer. Fluorescein amount in the samples was measured using 
Tecan Infinite 200 Reader at the excitation wavelength of 488 nm and emission wavelength of 
530 nm. Apparent permeability (Papp) was calculated according to: 
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Papp = (dQ/dt)*(1/A)*(1/C0)……….(eq1) 
Where dQ/dt is the amount of drug transported per time, A is the surface area of the 
monolayer and C0 is fluorescein concentration (µg/ml) at time 0. 
Permeability of FluNa across non-stimulated Caco-2 monolayers was determined as control. 
TEER of all monolayers was monitored before and after the transport studies to ensure the 
integrity of monolayer. 
 
2.3.9 Fluoresbrite polystyrene nanoparticles uptake in Caco-2 cell monolayer and co-
culture 
The experiments were conducted using Transwell-grown Caco-2 monolayers. 0.1% w/v 
Fluorescein-labeled polystyrene nanoparticles were added to the apical side and incubated at 
37°C for 4 hours. The medium was removed and cells were washed three times with PBS to 
remove excessive non-adhered particles. For the single culture the cells were then stained 
with ZO-1 labeling antibody and DAPI. The co-cultures were stained with DAPI dye for 
Caco-2 nucleus localization and analysis was done by CLSM imaging. Immunocompetent 
cells in the model were detected by their auto fluorescence in red spectra region (Laser 
excitation : 543 nm, emission: 560-615 nm). , fluorescein-labeled particles were detected in the 
green spectra region (Laser excitation : 488 nm, emission: 500-550 nm).  and DAPI in the blue 
spectra region (Laser excitation : 720 nm-multiphoton, emission: 390-465 nm).  
All the particles were monitored for their size and polydispersity index by Dynamic Light 
Scattering measurement using Zetasizer Nano ZS (Malvern Instruments, Herrenberg, 
Germany). Nanoparticle adherence to Caco-2 cells was quantified using images taken from 
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randomly chosen areas of the monolayer. The analysis was conducted by fluorescence 
distribution analysis with ImageJ software. 
2.3.10 Caco-2 monolayer mucus staining with alcian blue 
Tight Caco-2 monolayers cultured on Transwell filter insert for 21 days were washed twice 
with PBS. Alcian blue dissolved in 3% acetic acid was added to the monolayer and incubated 
for 20 minutes at room temperature. The excessive alcian blue was removed by washing 
three times with PBS. Afterwards microscopic monolayer images were taken with digital 
camera C5050 (Olympus, Japan). 
 
2.3.11 Mucus quantification by glycoprotein measurement 
Content of the main mucus glycoprotein mucin in stimulated and non-stimulated Caco-2 
cells was quantified using periodic acid/Schiff reagent method as described previously [57]. 
Briefly, Schiff reagent was prepared by dissolving fuchsin in 100 ml boiling water and letting 
the solution cool down to 50°C before adding 20 ml of IM HCl. Directly before experiment 
1.66 g sodium metabisulphite was added to the solution and incubate at 37°C until the 
solution is colorless or pale red.  
The medium of Caco-2 cell monolayer was carefully removed and the cells were lysed with 
100 µl PBS with 1% Triton-X addition. The samples were then incubated at 37°C for 2 hours 
with 10 µl periodic acid solution, which was prepared by adding 10 µl of 50% of periodic 
acid to 10 ml of 7% acetic acid. Afterwards, 10 µl Schiff reagent was added and samples were 
incubated at room temperature for 30 minutes before measuring adsorbtion at 555 nm using 
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Tecan Infinite 200 Reader spectral photometer. A calibration curve with a linear range  of 10 
– 600 µg/ml  was generated using porcine mucin.  
 
2.3.12 Macrophages and Dendritic cells cell culture 
Macrophages and dendritic cells were differentiated from blood monocytes originated from 
buffy coats (Blood donation service, Saarbruecken, Germany).  Buffy coats were processed by 
Ficoll density gradient centrifugation to obtain the peripheral blood mononuclear cells.  
These cells were plated with macrophages medium (RPMI medium supplemented with 10% 
human AB serum, 1% non-essential amino acid and 1% sodium pyruvate). Mature 
macrophages were obtained after seven days cultivation with macrophages medium while 
DCs were obtained after seven days cultivation with macrophages medium with addition of 
25 ng/ml IL-4 and 50 ng/ml GM-CSF. The harvested DCs and macrophages were analysed 
for their marker CD1a and CD14 by FACS measurement. 
 
2.3.13 Three-dimensional triple cell culture 
100 µl of DCs and macrophages dispersed in a 80%(w/v) solution of type I bovine collagen 
pH 7.4 at a concentration of 105 cells/ml were pipetted on top of 3460 Transwell filter inserts 
(1.12 cm2 area) resulting in a seeding density of approximately 104 cells/well. 1 hour later, 
6x104 Caco-2 cells were then seeded on top of the formed collagen gel layer. The co-culture 
was kept at 37°C in 5% CO2 with Caco-2 medium at the apical side and macrophage medium 
in basolateral compartment as illustrated in figure 2. After 21 days the co-culture was 
utilized for the experiments. For the inflamed model 10 ng/ml IL-1ß was added to the apical 
side and incubated for at least two days. Apical fluid was removed before experiment and 
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cells were washed three times with PBS to remove any IL-1ß leftovers. The TEER value was 
monitored before and after each experiment.  
 
 
 
Figure 2. Experimental set up of the co-culture consisting intestinal epithelial cell line, macrophages 
and dendritic cells. 
 
2.3.14 Sample preparation for histological staining 
Transwell filter inserts were stained with acid phosphatase reagent for one hour and washed 
with water and treated with ethanol multiple times before fixing with paraffin overnight. 
Acid phosphatase reagent was obtained by mixing 0.4 ml pararosanilin-HCl solution, 0.4 ml 
sodium nitrit, 0.5 ml naphtol ASB1 phosphate buffer and 9 ml Veronal buffer. The paraffin 
block was cut into 4 µm sections and mounted on glass slides. The histological cut was 
stained with Haemalaun solution for 5 minutes and washed with water before treatment 
with Eosin G for 30 seconds. The preparation was washed four times with 100% ethanol and 
xylol solution and later fixed with Roti-Histokitt. 
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2.3.15 Statistical analysis 
Student’s t-test and one way ANOVA was used to compare results from different treatments 
at different time points. The analysis was done with SigmaStat 3.0.Individual experiments 
were performed  at least in triplicate and each experiment was repeated at least once.  
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2.4 Results 
2.4.1 Inflammatory marker in mRNA level in Caco-2 cells after stimulation with pro-
inflammatory compounds  
First experiments for stimulation of inflammation were conducted by addition of LPS to the 
enterocyte cell lines T84, HT-29 and Caco-2. mRNA production from these cells was 
monitored at various time points from 0 to 24 h and the pro-inflammatory markers such as 
IL-8 and TNF-α were measured by real-time PCR. As can be seen in figure 3a & b T84 and 
HT-29 showed no response to the stimulation, while Caco-2 were the only responsive cells. 
Therefore the Caco-2 cell line was selected for all further experiments. 
Caco-2 cells showed a time-dependent increase of pro-inflammatory cytokine mRNA in 
response to the stimulation with bacterial LPS from S. typhimurium and E. coli. LPS from 
S.typhimurium showed higher impact on Caco-2 cells than LPS from E.coli increasing the IL-
8 expression by 40 to 70 and 2 to 20-fold respectively (Fig. 3a). IL-8 mRNA was upregulated 
in a concentration dependant way with the highest expression at the highest concentration of 
10 µg/ml of both bacterial LPS peaking immediately two and four hours after stimulation 
with a gradually decay afterwards.  
The stimulation with bacterial LPS also increased the expression of TNF-α which gave a 
similar pattern as IL-8 expression by having the highest expression in the cells treated with 
10 µg/ml bacterial LPS. LPS from E.coli slightly upregulates TNF-α only about 2-3 fold while 
LPS from S.typhimurium achieved about 10 fold induction (Fig. 3b.)  
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a) 
 
b) 
 
c) 
 
d) 
 
Figure 3. Expression of  IL-8 (a) and TNF-α (b) mRNA  in T84, HT-29 and Caco-2  intestinal epithelial cell 
lines in response to stimulation with E. coli or S. typhimirum LPS  as  determined by real time PCR. Effect of 
stimulation with IL-1ß alone or in combination with  LPS on IL-8 (c) and TNF-α (d) mRNA expression in 
Caco-2 cells. (mean ± SE, n=6, * indicates statistically significant differences compared to control, p<0.05; ** 
indicates statistically very significant differences compared to control, p<0.01). 
 
 
In addition to LPS, pro-inflammatory cytokine IL-1ß was also evaluated as a stimulant, but in 
Caco-2 cells only. Cells responded slower to stimulation with IL-1ß but to higher extent in 
comparison to LPS stimulation both in their IL-8 and TNF-α expression (Fig. 3 c and d). The 
value for IL-8 reached about 600 fold induction compared to the control value four hours 
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after stimulation with IL-1ß. No concentration dependent effect was observed in a range 
from 1 to 10 ng/ml IL-1ß (data not shown). IL-1ß stimulation in Caco-2 cells also increased 
TNF-α expression up to 100 fold compared to the control (Fig. 3d). 
Interestingly, co-stimulation of Caco-2 with both S. typhimurium LPS and IL-1ß yielded an 
increase of both IL-8 and TNF-α in similar level as stimulation with IL-1ß alone, but the 
response was faster: the cytokine release peaked already 2 hours after co-stimulation while 
the stimulation with IL-1ß alone resulted in a peak not before 4 hours (Fig. 3c and d).  
 
2.4.2 IL-8 protein release in response to pro-inflammatory compounds in Caco-2 
IL-8 protein release showed also an increase to the stimulation in both bacterial LPS in 
concentration-dependent manner. The non-stimulated control cells did not release a 
detectable amount of IL-8 protein while stimulation of 0.1-10µg/ml with LPS from both 
bacterial strains induced a release of 30 to 120 pg/ml IL-8 (Fig. 4).  
In comparison, IL-1ß in concentrations as low as 1 ng/ml induced a release of more than 500 
pg/ml IL-8; 10 ng/ml of IL-1ß induced more than 1500 pg/ml IL-8.  
The co-stimulation by IL-1ß and LPS (10 µg/ml) gave a similar IL-8 release as by stimulation 
with IL-1ß alone, but the maximal response was already reached at 5 ng/ml IL-1ß. No 
further increase was observed at 10 ng/ml IL-1ß. 
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Figure 4. Modulation of IL-8 protein expression in Caco-2 cells after exposure to varying concentration 
of LPS from E.coli, S.typhimurium, IL-1ß and double stimulation with IL-1ß and LPS from 
S.typhimurium. (mean ± SE, n=6, * indicates statistically significant differences compared to the lowest 
tested concentration of stimulant, p<0.05). 
 
2.4.3 Pro-inflammatory compound-induced increase of Caco-2 monolayer permeability 
Furthermore, the effect of inflammatory stimulation on Caco-2 cells barrier function was 
investigated via TEER measurement. TEER values of Caco-2 cells stimulated with both kinds 
of LPS resonated within limits of 90 - 110% of the unstimulated control value (data not 
shown). IL-1ß significantly decreased TEER to a nadir of 80% of the control value which was 
reached 72 h after stimulation as shown in figure 5a. Varying the concentration of IL-1ß 
within a range of 1 to 10 ng/ml had only marginal effect on TEER. Again, co-stimulation by 
IL-1ß and LPS from S. typhimurium resulted in a faster onset of the effect but did not further 
decrease the final TEER value (Fig. 5b).  
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                                     a) 
 
                                       b) 
 
Figure 5. Effect of varying concentrations of IL-1ß (a.) or a co-stimulation with IL-1ß and 10 µg/ml 
LPS from S.typhimurium (b.) on Caco-2 monolayer permeability measured by changes in 
Transepithelial Electrical Resistance (TEER) (mean ± SE, n=6, * indicates statistically significant 
differences compared to control, p<0.05; ** indicates statistically very significant differences compared 
to control, p<0.01 ). 
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2.4.4 Transport of fluorescein in inflamed Caco-2 cells 
Fig. 6  shows the fluorescein permeability in response to increasing concentrations of IL-1ß. 
The average Papp value in the control experiment with non-stimulated Caco-2 cells was the 
same for both apical-basolateral and basolateral-apical direction. After treatment with IL-1ß, 
TEER was decreased by up to 20% compared to control. Apical-basolateral transport was not 
affected by this relatively small change in TEER and only showed a marginal increase. 
However, basolateral-apical transport was increased by up to 84% when Caco-2 cells were 
stimulated with high doses of 500 ng/ml. 
 
 
Figure 6. Apparent permeability values of fluorescein transport across Caco-2 monolayers pre-treated 
with IL-1ß and the respective TEER values. (mean ± SE, n=6, * indicates statistically significant 
differences compared to control, p<0.05; ** indicates statistically very significant differences compared 
to control, p<0.01). 
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2.4.5 Immunostaining of tight junction protein ZO-1  
As the monolayer permeability was increased in response to the stimulation, the ZO-1 tight 
junctional protein was tracked with fluorescent labeled antibody. ZO-1 as the essential pore 
forming part of the tight junctional complex is normally located towards the apical side of an 
epithelium as can be seen in figure 7a. In IL-1ß stimulated cells, the ZO-1 showed less 
intensity at the apical side but reached deeper down to the basolateral side indicative of an 
reorganization process of the tight junction proteins (Fig. 7b). 
a) 
 
b) 
 
Figure 7. Immunofluorescence microscopy of Caco-2 cells, fixed and stained with antibodies specific 
for ZO-1 (red) and DAPI (blue) for nucleus dye, untreated control  (a), IL-1ß 10 ng/ml treated cells (b). 
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2.4.6 Nanoparticles allocation in non-stimulated and stimulated Caco-2 monolayers 
Nanoparticles of 100 nm size or larger were observed only on the apical side of Caco-2 
monolayers, indicating adherence to the cells but no uptake. There was no difference 
between stimulated Caco-2 cells (Fig. 8b) and the non-stimulated control (Fig. 8a). In contrast 
to all larger particles, the fluorescence signal of 50 nm nanoparticles was also located clearly 
below the apical cell membrane. Moreover, there was an increased signal in stimulated cells 
compared to the control (Fig. 8a and b) The signal was not co-localized with the ZO-1 signal 
in either case. This indicates that 50 nm particles may penetrate into Caco-2 cells and that 
there is more adherence of these particles to cells in state of inflammation. Furthermore, it 
seems particles were not transported through the cell-cell junction. 
Adherence of nanoparticles was quantified by calculating fluorescence distribution in the 
images taken randomly across the monolayer confirming the visual impression (Fig. 8). Only 
particles as small as 50 nm were significantly more accumulated in inflamed Caco-2 
monolayers compared to the control (Fig. 9).  
As can be seen from alcine blue staining and mucus quantification in figure 10a and b, 
inflammatory stimulation of Caco-2 cells was accompanied by an increased production of 
mucus of ~12%. 
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2.4.7 Three dimensional co-culture of Caco-2 cells with dendritic cells and monocytes 
As it is known for Caco-2 cells, monocultures form a tight monolayer when grown on a filter 
membrane, reaching a stabile value of TEER after 21 days in culture (Fig. 11a.). In the 
presence of macrophages and dendritic cells, the time course of TEER was slightly delayed 
after seeding, but later increased similarly as for the Caco-2 single culture, also reaching the 
same plateau after 21 days.  
Upon stimulation of the co-culture by adding IL-1ß to the apical compartment, TEER value 
of stimulated co-culture decreased to about 80% of the non-stimulated control values, 
similarly as previously observed with Caco-2 monoculture. There was no significant 
difference between the various combinations of the cells in co-culture (Fig. 11b). 
After IL-1ß removal, the monolayer did not immediately recover from the inflammation as 
can be seen from figure 11c. TEER was stable after the inflammation, increased gradually 
and recovered after 7 days. 
 
Figure 9. Quantification of adhered nanoparticles. Images of nanoparticles ranging in size from 50 to 
500 nm adhered to Caco-2 cells were taken from random areas by CLSM and the images were 
analysed by pixel counter from ImageJ software (mean± SE, n=3, * indicates statistically significant 
differences compared to control, p<0.05). 
3D in vitro model of inflamed colonic mucosa  
 
46 
 
a) 
 
l o                b) 
 
Figure 10. (a) Mucus layer  in non-stimulated Caco-2 cells (left) and in cells stimulated with IL-1ß 10 
ng/ml (right) all  cultured on Transwell filter insert and dyed with Alcian blue. (b) Mucus 
quantification in Caco-2 cells with Periodic acid/Schiff stain colorimetric assay (mean± SE, n=3, * 
indicates statistically significant differences compared to control, p<0.05). 
 
2.4.8 Release of IL-8 protein from the three-dimensional co-culture 
IL-8 protein release into both the apical and basolateral compartment of the Transwell 
system was compared between the co-culture and similar single culture set-up of Caco-2 
monolayer (Fig. 12). A marginal increase of IL-8 release in Caco-2 culture was obtained after 
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inflammation, both in apical and basolateral side. In contrast, co-culture seeded on Transwell 
filter insert released higher amount of IL-8 after stimulation with IL-1ß, reaching about 30-
fold induction in the basolateral side. Interestingly, there were more IL-8 released to the 
basolateral side in a non-inflamed condition but significantly higher IL-8 amount was 
released to basolateral side in comparison to the apical side in inflamed condition. The effect 
of IL-1ß stimulation is found to be much stronger in co-culture compared to the single Caco-
2 culture on Transwell filter. 
a) 
 
b) 
 
c)
 
 
Figure 11. TEER development of Caco-2 cells in the presence of various combination of macrophages and 
dendritic cells (a),  the influence of IL-1ß 10 ng/ml on the monolayer integrity (b), and recovery of TEER 
after removal of IL-1ß (c) (mean ± SE, n=6, * indicates statistically significant differences compared to 
control, p<0.05). 
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Figure 12. IL-8 protein release of  Caco-2 cells in single culture or in co-culture with macrophages and 
dendritic cells cultivated in Transwell filter insert after stimulation of inflammation with IL-1ß 
10ng/ml (mean ± SE, n=3, * indicates statistically significant differences compared to control, p<0.05). 
 
 
 
Figure 13. Histological image of the 3d triple co-culture with immune-competent cells and Caco-2 cells 
on Transwell filter inserts after hemotoxylin staining (a) and with additional specific acid phosphatase 
staining for macrophages(b). The macrophage was pointed out with an arrow and scale bars indicate 
100 µm. 
3D in vitro model of inflamed colonic mucosa  
 
49 
 
2.4.9 Optical image of three-dimensional co-culture by histological cut and CLSM 
Light-microscopy of paraffin embedded sections of the triple co-culture showed an intact 
monolayer of Caco-2 cells on top of the collagen layer, as can be seen from their blue nucleus 
hematoxylin staining (Fig. 13a). The collagen contained macrophages and dendritic cells. As 
defined by acid phosphatase staining (immune cells colored red), immune-competent cells 
were also found to be integrated into the cell monolayer or on top of it. (Fig. 13b). Findings 
were confirmed in CLSM picture (Fig. 14), in which both immunocompetent cells, dendritic 
cells and macrophages, could only be detected from their auto fluorescence and not be 
distinguished. This observation is a hint for the vitality and mobility of the immune-
competent cells which has been described to be able to migrate through the intestinal 
epithelium, reaching out for antigens present at the apical side, but still maintaining the 
overall tight junctional tightness and barrier function. 
 
Figure 14. CLSM images of the 3D co-culture. Caco-2 cell nucleus was dyed with DAPI (blue) and the 
autofluorescence of the immune-competent cells (red) were used for their detection. 
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a) 
 
b) 
 
Figure 15. Confocal Laser Scanning Microscope image of  a.) healthy and b.) inflamed intestinal mucosa model 
with 50 nm Fluoresbrite particles coupled with fluorescein (green) as model formulation. Nuclei were stained 
with DAPI dye (blue) while immunocompetent cells can be observed by their autoimmuno-fluorescence color 
(red). Uptake of nanoparticles by immunocompetent cells can be observed by colocalization signal in yellow. 
All images were captured in 630x magnification. 
 
2.4.10  Disposition of polystyrene nanoparticle in the triple co-culture  
Disposition of 50 nm polystyrene nanoparticles was investigated in the 3D co-culture 
stimulated with IL-1ß as well as in the non-stimulated control co-culture. In agreement with 
findings from the Caco-2 monoculture most of the nanoparticles adhered to the top of 
monolayer while some penetrated the Caco-2 cells (Fig. 15). However, also a strong uptake 
into the immunocompetent cells was observed. Uptake into immune-competent cells was 
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stronger in the inflamed model compared to the control as indicated by the stronger yellow 
co-localization signal of green nanoparticle fluorescence and red auto fluorescence of 
macrophages and dendritic cells. Furthermore, the immunocompetent cell population in 
non-stimulated control stayed mostly in basolateral side which represents the lamina propria 
side in vivo, while in the inflamed model there was an increased mobilization of 
immunocompetent cells to the apical side. 
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2.5 Discussion 
The intestinal epithelium serves as essential cell barrier between the gut lumen and the 
lamina propria. It is known for its robustness against invasion of luminal bacteria which 
may be present at concentrations of more than 1014 CFU/ml. This barrier normally does not 
react to commensal bacteria, but activates the pro-inflammatory signaling pathway only in 
the presence of pathogenic bacteria. In IBD however, coupled with an increased 
permeability, the barrier fails to perform such initial recognition probably due to lack of 
defensin molecules, displaying no reaction before the bacteria invade the basolateral side 
[58]. The exact signaling processes however, still remain unclear. 
Past in vitro studies of formulations targeting IBD have been conducted in conventional 
monoculture of cell lines. These cell lines represent the normal mucosa with intact tight 
junctions and strong barrier properties. However, such as test system does not reflect the 
pathophysiological changes happening in inflamed region of IBD. Moreover, a single cell 
line can never represent the complex interplay of different cell types during an 
inflammatory process. 
Stimulation of inflammation in a single cell line model 
One of the points to be taken into attention is that the loss of barrier in IBD is dependent on 
tight junctional intercellular permeability changes which is a function of cytokine 
production of immune cells instead of epithelial damage happening in tissue injury [59]. In 
the initial setting up of a more representative model of the intestinal barrier in the state of 
inflammation, we evaluated different intestinal epithelial cell lines (Caco-2, HT-29 and T84) 
in combination with several pro-inflammatory compounds (LPS from the commensal 
intestinal bacteria Escherichia coli and Salmonella typhimurium and the potent IL-1ß  for 
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their ability to mimic the in vivo pathophysiology of the inflamed intestinal mucosa, i.e. the 
release of pro-inflammatory markers, structural re-organization of tight junction proteins 
and subsequent changes in barrier properties. 
The problem in identifying a suitable cell line is that the most prominent epithelial cell lines 
are well known to be hyporesponsive to stimulation, which might be an advantage when the 
goal is to model an intact, non-inflamed intestinal mucosa. Several groups [60]8,19 found a 
general hyporesponsiveness of the polarized tight Caco-2 monolayer to various non-
pathogenic bacteria except for increased level of human β-defensin-2 [61]. They also 
reported that stimulation of Caco-2 with IL-1ß or TNF-α from basolateral side induced 
strong increase of IL-8 and TNF-α but found no stastistical significance [61].This was 
confirmed in part in our experiments: as shown by real time PCR, HT-29 and T84 were 
unaffected by LPS stimulation and showed no increase in IL-8 and TNF-α expression. Only 
Caco-2 cells could be stimulated by LPS and were therefore chosen as the enterocyte cell line 
for all future experiments. 
Inducing an inflammation, LPS acts via extracellular toll like receptor 4 (TLR4) and  
subsequent  signaling cascades which activate the ubiqutination of IκB leading to the 
translocation of NF-κB into the nucleus and activation of the inflammation process [62]. 
Some of the molecules downstream of this inflammation signaling process are pro-
inflammatory cytokines such as TNF-α and IL-8, which can be therefore used as markers to 
quantify the inflammatory reaction. TLR4 has been found in low level in healthy intestine 
but highly upregulated in IBD and has also been shown to be expressed in epithelial cells.  
Stimulation with LPS from both E. coli and S. typhimurium was sufficient to increase the IL-
8 and TNF-α mRNA production in Caco-2 cells in our experiments in a time and 
concentration dependent manner, with highest mRNA levels being detected as early as 2h 
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after stimulation. LPS stimulation of inflammation in Caco-2 cells has already been observed 
in previous studies [63], although Abreu et al  attributed the pro-inflammatory effect to a 
contamination of lipoprotein in the purified LPS and an activation of TLR2 [64]. A 
contrasting report showed a hyporesponsiveness of Caco-2 cells to LPS [65] which was 
ascribed to a lack of MD2 expression, a partner molecule for TLR4 in the signaling complex. 
The up-regulation of IL-8 and TNF-α mRNA expression after stimulation with LPS in our 
experiments, was not reflected at the protein level and in TEER change. It seems that the 
weak pro-inflammatory stimulus by LPS is counterbalanced by the simultaneous activation 
of anti-inflammatory processes.  This is not unexpected, as Salmonella typhimurium and 
Escherichia coli themselves have been described as nonpathogenic microbiotas with 
attenuated inflammatory response from epithelial cells. Instead the TLR recognition signal 
even helps the epithelium by protecting it from non-specific damages [66]. In vivo, additional 
various immune cells are present on the lamina propria side of epithelium and regulate the 
immunity towards external stimuli by secreting pro-inflammatory cytokines.  
As LPS stimulation was not effective enough, a number of cytokines were evaluated as 
alternative inductors of inflammation. The potent cytokine IL-1ß had a strong effect, 
stimulating a 10-fold higher IL-8 release both at mRNA and protein level using only 1/10 of 
the concentration compared to LPS. The up-regulation of IL-8 mRNA production after IL-1ß 
stimulation was not as fast as after LPS stimulation peaking after 4 h instead of 2 h. While 
LPS is being recognized by TLR-4, IL-1ß is recognized by other receptor IL-1R on the cell 
surface which may give a delay in recognizing and the response in the subsequent 
downstream signaling pathway. Although both receptors are classified in one super family 
[67] and were suggested to share a common pathway in activation of inflammation, a 
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specific MyD88-independent pathway may exist for the LPS signaling cascade which leads 
to a difference in downstream signaling pathways [68],[69]. 
Interestingly, double stimulation of both IL-1ß and LPS from S. typhimurium showed a 
similar level of mRNA up-regulation as the single stimulation with IL-1ß, but showed a 
progression curve comparable to stimulation with LPS reaching its maximum after 2 hours 
and normalizing after 4 hours. This indicates a process where LPS may initialize the 
stimulation and increase the susceptibility of the signaling pathway for IL-1ß without 
actually increasing the signaling pathway activity. Similar to the effect on mRNA 
expression, double stimulation of the cells with IL-1ß and S.typhimurium LPS did not 
further increase the IL-8 production, which hints at a saturation effect of the inflammation 
machinery in Caco-2 cells. IL-1ß has been singled out to affect the pro-inflammatory 
cytokines excretion in Caco-2 cells predominantly compared to other factors [70], as a factor 
with wide-range of inflammatory activities [71] and markedly upregulated in IBD [72]. It has 
been hypothesized being one of the prominent pathogenic factor in IBD beside other genes 
such as IL-18 [73] and CD14 [74] due to the fact that the severity and the course of the 
inflammation was correlated to high occurrence rate of IL-1ß gene polymorphism in CD 
patients [75]. 
In contrast to LPS, IL-1ß was also proficient enough to decrease tight junction integrity and 
epithelial barrier function as seen in a drop of TEER values to about 80% of the non-
stimulated control and transport data for the paracellulary transported dye fluorescein 
sodium. A double stimulation by LPS and IL-1ß did not further increase the permeability 
than the stimulation with IL-1ß alone. This result is in line with the data on IL-8 production 
which also indicate saturation in the inflammatory signaling.   
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The activation of inflammation process through NF-κB pathway has been shown to increase 
the tight junction permeability on those cells through phosphorylation of myosin L chain 
kinase (MLCK) which induces a contraction in actin-myosin filaments [76], a process that is 
thought to be central for loss of barrier function in inflammatory bowel disease [77]. Tight 
junction protein ZO-1 and adherens junction protein E-cadherin are directly coupled to the 
actin filaments and thus re-organize as a result of the contraction. This change in ZO-1 
structure was visible in our immunofluorescent staining of the protein.: Looking at 
distribution of ZO-1 protein in stimulated Caco-2 cells, the tight junctional protein was still 
detectable but seemed to be thinner with the strands reaching down to the basolateral side 
of the monolayer. A similar observation has been reported by Clayburgh et al38, which have 
shown a rearrangement of ZO1 to the tricellular junction. In contrast the organization of 
other tight junctions proteins such as Occludin and Claudin-1 not directly connected to the 
actin skeleton was unchanged in IL-1ß treated Caco-2 cells compared to non-stimulated 
cells. Overall expression of tight junction proteins including ZO-1 was unchanged as 
indicated by real time PCR results (data not shown). The structural change in the tight 
junctions serves as an explanation of the statistically significant but rather modest drop in 
TEER of 20-25%, Instead of a complete loss of tight junctional integrity and destruction of 
the intercellular contacts, the tight junctions simply become more leaky enabling easy and 
fast invasion of monocytes between the cell monolayer and to the apical side.    
Studies with other pro-inflammatory compounds, such as IL-8, TNF-α alone or in 
combination with IFN-γ did not yield a decrease of TEER (data not shown). This is in 
contrast to previous reports on Caco-2 cells which showed a decrease of TEER value after 
stimulation with TNF-α [78] or in combination with IFN-γ [79]. The first study reported the 
drop of TEER value after 48 hours period stimulation with TNF-α to almost 40% reduction 
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while the second publication shows the drop only after stimulation of the cells with TNF in 
combination with IFN-γ, which in turn induced TNFR2 up-regulation and mediated the 
TNF-induced MLCK-dependent barrier dysfunction. It has not been clear if possibly 
different clones of Caco-2 cells have been utilized in both studies; however in this report we 
were using the C2Bbe1 Caco-2 clone which may have responded differently than the 
parental Caco-2 cells. 
Increased monolayer permeability in state of inflammation was observed also in an 
increased level of transport of paracellulary transported dye fluorescein sodium. In cells 
exposed to the highest tested concentration of 500ng/ml IL-1ß, the apical to basolateral 
transport was increased to about 15% while the basolateral to apical transport was 
significantly increased to 85%, each compared to the unstimulated control (Fig. 6).  
The translocation of polystyrene model nanoparticles through cell monolayer was found not 
to be affected by the pathophysiological changes. Smaller nanoparticles ~50 nm size were 
taken up by the cells, while bigger nanoparticles (>200nm) only adhered to the cell surface 
but were not transported to the basolateral side. There were no observable differences in 
uptake or translocation between stimulated and unstimulated cells. However there seemed 
to be an increase in number of particles adhering to the inflamed tissue. This observation 
was further verified by the nanoparticle quantification using ImageJ calculation software. 
Significantly more 50 nm nanoparticles adhered to inflamed monolayer compared to the 
non-stimulated control. The distribution pattern of the particles in the confocal pictures hints 
at an association of particles to mucus patches on the cell monolayer. The mucoadhesive 
interaction of nanoparticles has been described in previous publications as depending on the 
structure of polymeric chain surface and its hydrophilicity [80]. However, the report did not 
observe dependence on particle size and molecular weight of molecules on the particle 
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surface. In contrast, our observations showed size dependence in transit rate of 
nanoparticles. Smaller particles may adhere to the mucus easier than bigger aggregates and 
therefore increase their transit rate in the intestinal tissue. 
We quantified mucus production in stimulated and non-stimulated Caco-2 cells using alcian 
blue staining and mucin quantification by periodic acid/ Schiff reagent.  Indeed mucus 
production in IL-1ß stimulated Caco-2 cells was statistically significantly increased, which is 
in line with reports on CD patients in which hypertrophy of goblet cells [46], leading to 
increased mucus formation was observed. Furthermore, IL-1ß has also been shown to cause 
a rapid increase of mucin in HT-29-CL.16E cells, reaching 200% higher amount of mucin. 
However, this was observed in HT-29 cell line, which is a model for goblet cells and Caco-2 
cell as an enterocyte model is known to only produce very small amount mucus under 
normal condition. Our finding shows that even with low amount of mucus, its production is 
also affected after stimulation by pro-inflammatory cytokine IL-1ß in Caco-2 cells although 
to a lesser degree compared to the goblet cells.   
Stimulation of inflammation in a co-culture model 
Although we could stimulate an inflammatory reaction in Caco-2 cells which was 
accompanied by changes in the epithelial barrier properties and increased mucus 
production, the monoculture is not able to mimic the recognition of antigens by the 
intestinal innate immune system and the following interplay of cells. Therefore, a co-culture 
model was established which also contains dendritic cells and macrophages as the 
immunocompetent cells of the intestinal barrier. 
Previously, different 3-dimensional in vitro models have been utilized to study healthy 
intestinal systems, mostly using various co-cultures of intestinal epithelial cells and 
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immune-competent cells. des Rieux et al [14] combined Caco-2 and Raji B cells to induce M-
cell development. They found that Raji cells in co-culture with Caco-2 cells could drive their 
differentiation into M-cells, which are able to take up polystyrene nanoparticles >200nm by 
non-specific endocytosis. As a consequence, nanoparticle transport in this model was 50-fold 
higher in comparison to the monoculture. Other researchers have been working with 
various combinations of epithelial cells and either primary or macrophages cell lines, with 
some groups using fibroblast cells as feeder support. In most cases, the models were 
assembled on a polycarbonate filter inserts as they allow the mimicking of compartmental 
separation between lumen and lamina propria. Co-cultivation of HT-29 epithelial cell line 
with PBMC monocytes and primary intestinal fibroblasts led to aggregation of fibroblasts in 
the co-culture and phenotype change of the macrophages towards intestinal macrophages 
[15]. The intestinal epithelial cells co-cultured with PBMC-derived DC released exosomes 
that are capable to bind human serum albumin and interact preferentially with DCs [16]. 
Other co-culture studies with Caco-2 cells and activated monocyte cell line THP-1 showed 
apoptotic and necrotic effect to the Caco-2 cells besides damaging monolayer integrity.  A 
similar model has also been established to construct the respiratory tract using epithelial 
cells and immunocompetent cells to study the particles distribution [23] and the 1 µm 
particles were found to be taken up into all three cell types used. 
For specific inflammatory bowel disease model there has been a few approaches using 
primary blood cells from IBD patients and Caco-2 or primary colonic crypts cells. This 
model has shown that cells from IBD patients produced more IFN-γ than the healthy model 
but did not give any pathophysiological relevance because although cells were cultured 
together, they are not cultured to assembly the physiological arrangement in the intestine 
[81]. Besides, primary cell isolation is known to be arduous and problematic because of cells 
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origin from different individuals with various degrees of inflammation. Therefore, we 
propose this new model which consists of the relevant cells for the inflammation and 
antigen presenting signaling, allows controlled stimulation, and mimics major 
pathophysiological changes occurring in IBD 
For our setup, the immunocompetent cells obtained from periphery blood mononuclear cells 
were analysed by FACS and macrophages and dendritic cells expressed CD14+/CD1a- and 
CD14-/CD1a+ respectively (data not shown). As macrophages and dendritic cells were to be 
co-cultured with Caco-2 cells, we also tested the pre-conditioning of these cells with medium 
from Caco-2 cultivation. Pre-conditioned macrophages showed a loss of CD14 expression 
(data not shown), in agreement with their differentiation into intestinal macrophage like 
state. A previous study showed that co-culturing macrophages with intestinal epithelial cell 
line HT-29 also drove the differentiation of the blood derived macrophages towards the 
phenotype of intestinal macrophages [15] and intestinal macrophages have been 
characterized as non-reactive with down-regulated expression of CD14, CD16 or CD80 [82].  
Dendritic cells cultivated with Caco-2 secretion medium showed an increased CD1a 
expression (data not shown), which in turn showed a differentiation shift toward Th1 cells 
which are more responsive to stimulation from their environment and are responsible for 
antigen probing from the lumen and M-cells in vivo [15, 83-85]. DCs in IBD patients are also 
characterized by an upregulation of CD1a [86].We therefore conclude that the co-cultivation 
of dendritic cells and macrophages together with the epithelial cells for three weeks is not 
only necessary for the monolayer formation in the co-culture model, but also allows the pre-
conditioning which drives the differentiation of these cells towards a more intestine-like 
characteristic . 
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The co-culture itself showed the expected arrangement with Caco-2 building the monolayer 
on top of the culture while macrophages and dendritic cells were embedded in the collagen 
layer beneath the monolayer, though this condition seemed to be not static as in various 
areas we find immunocompetent cells mostly to be located directly under the epithelial layer 
and even reaching out to the apical side of the model (Fig. 13a). Some studies had reported 
the finding that antigen delivery across the intestinal barrier may either be conducted by 
specialized M-cells [87] or by direct probing by DCs from the lamina propria [88]. The 
mobility of immunocompetent cells in our model supports the latter theory and showed the 
viability of the immunocompetent cells in the co-culture. Caco-2 showed a similar 
development of tight junction in the presence of macrophages and dendritic cells as 
compared to the single cell culture.  TEER reached a plateau after 20-21 days in culture at 
600 -800 Ω*cm2 and dropped to 80% compared to the non-stimulated control, in agreement 
with findings from the stimulated monoculture.  
In contrast, IL-8 protein release into the medium in response to the pro-inflammatory 
cytokine IL-1ß was significantly higher in the co-culture in comparison to the Caco-2 
monolayer model particularly to the basolateral compartment. Cytokine release in co-culture 
has been investigated by several groups previously, Haller et al. showed  increased cytokine 
(TNF-α and IL-1ß) release in of co-culture of Caco-2 und PBMC also stimulated with IL-1ß 
[22]. Addition of PBMCs from healthy donors was shown to trigger the susceptibility of 
epithelial cells to non-pathogenic E. coli bacterial challenge [89], possibly by nitric oxid 
release that inhibit the gap junction of the enterocytes [14]. However, in these setups freshly 
isolated PBMCs were cultured with Caco-2 cells for one day before stimulation and the 
experiments were aimed to study the pathogenesis and the mechanistic undergoings after 
bacterial challenge in the inflamed intestine. Our setup is different in the objectives, cell 
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composition and structure, as our main aim is to mimic the pathophysiological changes and 
use the model for drug and drug formulation testing. We cultured macrophages and 
dendritic cells together with Caco-2 cells for 21 days to generate a tissue-like architecture 
with tight monolayer and active immune cells compartment which emulate the intestinal 
barrier. 
 The increased pro-inflammatory activity in the co-culture model is also reflected in the 
activity of the immunocompetent cells themselves. After stimulation with IL-1ß, we 
observed more immunocompetent cells mobilized to the apical side in inflamed model in 
comparison to healthy model. In particular, an increase in red signal at the surface of the 
Caco-2 monolayer is observed which might be ascribed to dendrites extending to the apical 
side of the monolayer or an increased invasion of immune cells. 
Furthermore, these stimulated immune cells were highly active in sampling nanoparticles. 
Comparing nanoparticle disposition in the stimulated co-culture vs. the non-stimulated 
control, an increase in yellow signal, i.e. co-localization of red signal from the immune cells 
and green signal from the nanoparticles can be detected. In contrast, particle disposition in 
the non-inflamed control is dominated by particle endocytosis into the epithelial cells as 
indicated by the predominant green signal in the region of the epithelial nuclei.  
Looking at the confocal images, we can identify two different populations of 
immunocompetent cells, one which embraced the particles and another population which 
tended to take less particles up. As both macrophages and dendritic cells were imaged using 
their auto fluorescence, we could not distinguish between them. Several attempts have been 
conducted to stain the immunocompetent cells with specific antibodies for their recognition. 
This approach has been unsuccessful so far since the immunocompetent cells in the co-
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culture had undergone a differentiation and lost some of their markers, as discussed above. 
However, seen from their characteristic behavior, we assume that dendritic cells are more 
likely to take the particle up from the apical side. The particles may later be transferred to 
macrophages and be digested, or further processed to the T-cells.  
This preferential uptake of nanoparticles by immunocompetent cells in the inflamed setup is 
in contrast to our observations in the stimulated Caco-2 single cell culture where polystyrene 
nanoparticles of the same size (50 nm) accumulated only in the intestinal epithelial cells and 
were internalized to a lesser degree. Thus studying particle interaction with the inflamed 
intestinal barrier in a single cell model would lead to potentially both underestimating as 
well as misjudging particle disposition.  
In conclusion, this three-dimensional cell culture model will be an efficient tool for 
narrowing the gap between conventional cell culture system and animal testing, providing a 
pathophysiological relevance of inflamed tissue, while maintaining the convenience of cell 
culture. 
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3. Screening of budesonide nanoformulations for treatment of 
inflammatory bowel disease in an inflamed 3D cell-culture model 
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3.1 Abstract 
Drug formulation screenings for treatment of inflammatory bowel disease (IBD) are mostly 
conducted in chemically induced rodent models that represent the acute injury-caused 
inflammation instead of chronic condition. To accurately screen drug formulations for 
chronic IBD, there is an urgent need for a relevant model that mimics the chronic condition 
in vitro. In order to reduce and potentially replace this scientifically and ethically 
questionable animal testing for IBD drugs, our laboratory has developed an in vitro model 
for the inflamed intestinal mucosa observed in chronic IBD, which allows high-throughput 
screening of anti-inflammatory drugs and their formulations. The in vitro model consists of 
intestinal epithelial cells, human blood-derived macrophages and dendritic cells that are 
stimulated to inflammation via IL-1ß. In this study, the model was utilized for evaluation of 
the efficacy and deposition of budesonide, an anti-inflammatory drug, in three different 
pharmaceutical formulations:  (1) a free drug solution, (2) encapsulated into PLGA 
nanoparticles, and (3)encapsulated into liposomes. The in vitro model of the inflamed 
intestinal mucosa demonstrated its ability to differentiate therapeutic efficacy among the 
formulations, while maintaining the convenience of conventional in vitro studies and 
adequately representing the complex pathophysiological changes in vivo.  
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3.2 Introduction 
Inflammatory bowel diseases (IBD), encompassing among ulcerative colitis (UC) and 
Crohn’s disease (CD), are a group of chronic, remitting inflammatory diseases affecting the 
gastrointestinal tract. Combination of genetic predisposition and environmental factors are 
the main causes to a de-regulated immune system  resulting in aberrant mucosal 
inflammation [90]. Due to the impaired integrity of the epithelial barrier, both UC and CD 
are characterized by increased luminal antigen uptake [91, 92]. As an incurable disease, 
current therapies are directed towards induction of remission during acute episodes and 
prevention of relapses [93]. Treatment depends on the site of disease and its severity While 
UC is restricted to the colon and rectum, CD is discontinuous and can affect any part of the 
gastro-intestinal tract. Common anti-inflammatory approaches include 5-aminosalicylates, 
antibiotics, corticosteroids, immunosuppressants, anti-TNF antibodies and other biological 
agents, such as cytokines [94-96]. These therapies are very promising but expensive. The 
standard treatment for moderate to mild cases consists of  budesonide at a daily dose of 9 
mg [97]. Although associated with less adverse effects compared to other corticosteroids, 
budesonide has demonstrated higher adverse effect compared to the placebo due to 
extensive first pass metabolism and low systemic bioavailability [98]. These adverse effects 
can be reduced by selectively delivering budesonide to its site of action. 
The route of delivery for budesonide may be rectal, oral, or in some cases, intravenous. 
Rectal formulations are very effective for treatment in distal colonic areas and thus are 
mainly used in UC. For oral delivery, the drug compound has to resist or be protected from 
the acidic pH of the stomach and the metabolizing enzymes of the intestinal flora. Thus, 
orally applied anti-inflammatories, such as budesonide, tend to be administered at higher 
doses, increasing the risk of systemic adverse effects. Many drug delivery strategies have 
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been tried to circumvent this problem, e.g. pro-drugs, which are only activated in distal 
intestinal areas, and coated pellets or capsules. These approaches, however, show limited 
bioavailability at the sites of inflammation mainly due to rapid elimination as a result of 
diarrhea, which is a common symptom in IBD. Furthermore, budesonide is a hydrophobic 
compound and highly insoluble, demonstrating low local bioavailability.  
A promising approach to increase the bioavailability and enhance the retention time of 
budesonide at the target site is via bioadhesion is through the use of nano-sized carriers. 
Nanocarriers can avoid the diarrhea symptom and  passively accumulate in the inflamed 
intestinal tissue [99]. Although the exact mechanism of accumulation is not fully 
understood, similarities to the enhanced permeability and retention phenomenon observed 
in cancerous tissues are assumed. Additionally, nanocarriers can be taken up by intestinal 
macrophages and dendritic cells. Then, the encapsulated drugs are released upon the 
degradation of the nanocarrier in the desired areas [100]. This passive targeting to the 
inflamed intestinal tissue using nanocarriers was successfully applied with different kinds of 
drugs (e.g. tacrolimus, rolipram and 5-ASA) and different nanocarrier technologies by 
showing increased therapeutic efficacy and reduced adverse effects compared to free drug 
molecules [96, 97, 101]. Formulation development and testing in these studies was 
conducted in different rodent models of colitis based on the chemical induction of an acute 
inflammation by dextran sodium sulfate (DSS) or tri-nitrobenzene sulfonic acid (TNBS). [99, 
102].  
Although the DSS and TNBS rodent models are accounted to be the most widely used 
animal model for IBD, these models display several major disadvantages. Besides the 
obvious ethical issues, species differences and the methods of stimulation have lead to 
overestimated or false results: Chemically induced models focus on the damage to the 
Screening of IBD drug formulations in inflamed 3D cell-culture model  
 
69 
 
epithelial barrier and the subsequent immune reaction, but fail to take into account the 
disregulation of the innate or adaptive immune system. [103] The disregulation of the 
immune system can affect both the response of certain drugs and the interaction with nano- 
or microcarriers. In addition, the genetic background of the animals can influence the 
pathogenesis. TNBS colitis in BALB/c mice presented a more Th2 type response while a Th1 
response was observed in SJL mice [104]. Thus, these models lack responsiveness to IBD 
drugs, such as corticosteroids and 5-ASA, and are not suitable to study the respective anti-
inflammatory formulations [54]. 
Disease relevant in vitro cell culture models based on human tissues may present a 
promising alternative for drug formulation testing as they allow for higher throughput, 
reduction of animal testing, and may provide insight into mechanisms of action, uptake and 
deposition. Such an in vitro model of the intestinal mucosa in the state of inflammation was 
previously established in our lab. The three dimensional model is based on the co-culture of 
intestinal epithelial Caco-2 cells with primary, blood derived macrophages and dendritic 
cells as components of the intestinal innate immune system [105]. All cells in the model are 
of human origin, eliminating issues with species differences often associated with the 
different animal models.  During 21 days of co-culture to allow tight barrier formation, 
immune cells assume an intestinal phenotype [15]. The incorporation of immunocompetent 
cells is crucial for the inflammation stimulation. They significantly enhance the 
inflammatory response after induction by cytokine IL-1ß addition, quantified via markers of 
inflammation such as increased IL-8 or TNF-α expression. As previously shown, the 
stimulated model reflects the pathophysiological changes observed at the intestinal barrier 
in IBD patients such as re-organization of tight junctions, reduced barrier properties, 
increase immune cell activity, release of pro-inflammatory markers and increased mucus 
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production, providing several parameters to monitor disease status and therapeutic activity 
of novel anti-inflammatory compounds and formulations. 
In this study, two different nanocarriers were evaluated using the established in vitro model 
for their efficacy in inflammation treatment. One nanocarrier was generated from PLGA, an 
FDA approved polymer material. PLGA has been widely investigated as a scaffold for tissue 
regeneration and as a drug delivery vehicle in the form of implants and nano- or microsized 
carriers. It is prominently featured for the oral delivery route due to its biodegradability, 
biocompatibility, and its ability to accommodate a wide range of compounds. Although the 
hydrophobic nature of PLGA benefits small hydrophobic compounds, the carrier has 
demonstrated to be versatile by loading biomacromolecules, such as insulin, peptides, 
antigens, and nucleic acids [106]. Thus PLGA nanoparticles can improve oral bioavailability 
of poorly soluble and permeable drugs by increased translocation and transcytosis and 
target compounds to their site of action in the gastrointestinal tract  for IBDs and potentially 
for colorectal tumors [107]. 
In contrast to the popularity of PLGA nanoparticles, there are only few studies that exploit 
liposomes for oral drug delivery applications. Instead, liposomes are commonly applied 
intravenously for a variety of  treatments from antibiotics to vaccinations [108] and tumor 
therapies [109]. Typically, PEGylated stealth formulations are employed for liposomes, 
reducing recognition by the reticuloendothelial system and affording prolonged circulation 
time in blood. The prolonged circulation half-life together with high flexibility allows 
liposomes with sizes 100-200 nm to extravasate through the leaky vasculature in tumors and 
inflamed organs and thus passively target their site of action [109, 110]. The comparable 
passive targeting principle for malfunctioning endothelium and epithelium has not been 
extensively explored yet for liposomes in IBD treatment. Few groups have tried to approach 
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the inflamed intestinal mucosa via the endothelium “backside” after intravenous delivery 
[111, 112]. Due to rapid degradation in the harsh gastric environment, liposomes are rarely 
applied via the luminal side of the intestine, and so far, the Rubinstein lab has addressed the 
approach for IBD therapy after rectal application [113, 114].  
With the current aims (1) to rationally develop novel nanomedicines for oral  and rectal IBD 
treatment, (2) to better understand the mechanism of nanocarrier interaction with the 
inflamed barrier and (3) to evaluate the power of the in vitro model to differentiate between 
different treatments, we studied two different types of drug delivery vehicles (polymeric 
PLGA nanoparticles and liposomes) for glucocorticoid budesonide, comparing their anti-
inflammatory activity and  ability to recover epithelial barrier function in the novel 3D cell 
culture model of the inflamed intestinal mucosa. Budesonide loaded nanoformulations were 
prepared, characterized and applied to the in vitro model, using the free drug solution and 
blank nanocarriers as controls. IL-8 release was measured for inflammation monitoring. 
Transepithelial electrical resistance was monitored to observe recovery in epithelial barrier 
function. Furthermore, particle deposition was studied using confocal laser scanning 
microscopy.  
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3.3 Materials and methods 
3.3.1 Materials 
Poly(L-lactide-co-glycolide) (PLGA) (Resomer RG 503 H; inherent viscosity 0.31 dl/g) was 
bought from Boehringer Ingelheim (Ingelheim, Germany). Budesonide was also gifted 
kindly from Boehringer Ingelheim. Polyvinylalcohol Mowiol 4-88 (PVA) was purchased 
from Kuraray (Frankfurt am Main, Germany). Human colon adenocarcinoma cell line Caco-
2 clone C2Bbe1 was obtained from American Type Culture Collection (Rockville, MD, USA). 
Dulbecco’s modified Eagle’s medium (DMEM), Fetal calf serum and non-essential amino 
acids were purchased from PAA (Pasching, Austria). Trypsin/EDTA was obtained from 
Lonza (Basel, Switzerland). Polycarbonate Transwell inserts with pore size 0.4 µm were 
purchased from Corning Incorporated (Acton, MA, USA). GM-CSF and IL-4 were obtained 
from R&D Systems (Minneapolis, USA) and IL-1ß from Promokine (Heidelberg, Germany). 
Ficoll Paque plus for PBMC isolation was obtained from GE Healthcare (Uppsala, Sweden) 
and human serum from Invitrogen (Wisconsin, USA). CBA human IL-8 Flex Set was 
purchased from BD Biosciences (Heidelberg, Germany). Purecol collagen was obtained from 
Advanced Biomatrix (Tucson, AZ, USA). 5-Fluoresceinamin (FA) and 1-ethyl-3-(3-
Dimethylaminopropyl)-carbodiimide hydrochloride and all other chemicals were obtained 
from Sigma (St. Louis, MO, USA). All chemicals used in this study were of highest analytical 
grade. 
 
3.3.2 Fabrication and characterization of budesonide loaded PLGA nanoparticles  
Fluoresceinamine labeling of PLGA (FA-PLGA) was conducted as described previously 
[115]. From this modified polymer budesonide loaded FA-PLGA nanoparticles were 
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prepared using emulsion solvent evaporation method [116, 117]. Briefly, 45 mg of 
budesonide base was dissolved at room temperature in 15 ml of ethylacetate containing 300 
mg of FA-PLGA. This organic phase was thereafter added via a gear pump (Gilson 
Minipuls, France) to an aqueous 2 % PVA solution under stirring. The emulsion was stirred 
for 2 hours at room temperature before homogenizing at 13,500 rpm for 10 minutes using an 
Ultra Turrax T-25 (Janke and Kunkle GmbH KG, Staufen, Germany). To this, emulsion water 
was added drop wise under stirring to a total volume of 80 ml. The organic solvent was 
evaporated overnight at room temperature and precipitated nanoparticles with 
encapsulated drug were then separated from free budesonide by tangential flow filtration 
using a Vivaflow 50 cassette (Sartorius, Goettingen, Germany) with a MW cut-off of 30k Da 
and a total washing volume of 500 ml.  After freeze drying in the presence of 300 mg of 
sorbitol as a cryoprotectant, nanoparticle were stored at 4°C under light protection until 
further use.   
FA-PLGA budesonide nanoparticles were characterized for their size, size distribution and 
surface charge after 1:10 dilution with purified water using Zetasizer Nano ZS (Malvern 
Instruments, Herrenberg, Germany). 
Encapsulation efficiency of budesonide in FA-PLGA nanoparticles was determined by 
dissolving 10 mg of freeze dried particles in 10 ml of ethyl acetate under stirring for 4 to 5 
hours. Then after complete evaporation of ethyl acetate the residue was dissolved in 5 ml of 
acetonitrile: phosphate buffer pH 3 (4:6) for 2 hours. The solution was then filtered through a 
disposable syringe filter paper (CHROMAFIL GF/PET 45/25) pore size 0.45 µm. 1ml of the 
clear filtrate was collected and analysed by HPLC. 
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The drug release was assessed by ultracentrifugation method. 5-10 mg of washed and freeze 
dried nanoparticles were dispersed in 5 ml PBS of pH 6.8 and 100 µl aliquots of this solution 
were added to 1.5 ml PBS in a ultracentrifugation vial, respectively and incubated at room 
temperature at a constant shaking speed of 500 rpm . At particular time intervals (1, 2, 4, 6, 
24 and 48 hours) one sample tube was centrifuged at 244,000 g for 25 minutes at 25°C. 1 ml 
of supernatant was thereafter removed from the nanoparticle pellet and quantified by 
HPLC.  
Budesonide content in the samples was quantified via HPLC (UltiMate® 3000, Dionex, 
Germany) using a reversed phase C18 Column (4.6 X 250 mm, pore size 5µm) (Merck KGaA, 
Germany). Mobile phase consisted of a mixture of phosphate buffer (pH 3) and acetonitrile 
(60:40) delivered at a flow rate of 1.900 ml/min. The injection volume was 80 µl and the 
retention time was 6.0 min for each sample with detection wave lengths of 214 and 254 nm. 
The method was linear (r2 = 0.9997) over a range of 20 ng/ml to 500 µg/ml, with a limit of 
quantification of 347 ng/ml. 
 
3.3.3 Liposome fabrication 
DPPC, PEG2000-DSPE (Lipoid) and cholesterol were weighed in a 1.85:0.15:1 ratio in a 50 
mL round bottom flask and dissolved in 5-10 mL ethanol (absolute) by heating at 50ºC. The 
organic phase was evaporated using rotary evaporation resulting in a dry lipid film, which 
was dried further under nitrogen flow for 30 minutes.  Due to better water solubility 
budesonide phosphate instead of the free base was used in the preparation of the liposomes. 
The drug was dissolved in reversed osmosis water at a concentration of 100 mg/ml. The 
lipid film and corticosteroid solution were heated to 50ºC before adding the solution to the 
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film. The film was hydrated for 5-10 min using a rotary evaporator without applying 
vacuum. After hydration, the size and polydispersity was decreased by extruding the 
dispersion through two polycarbonate filters. Starting with two extrusions through a double 
200 nm filter and two extrusions through 200 and 100 nm filter, the liposomes were extruded 
ten times through two 100 nm filters.  Free corticosteroid not encapsulated into the 
liposomes was removed by means of dialysis (MWCO 30,000 Da) in PBS at 4-8 ºC for 48 
hours, where the PBS was refreshed regularly in order to remove all free corticosteroid. As 
for the PLGA particles size and polydispersity and of the liposome formulations were 
measured by size Dynamic Light Scattering using Zetasizer Nano ZS.  
 
3.3.4 Setting up of co-culture 
Co-culture was assembled and cultivated as described previously [105].  Briefly, dendritic 
cells and macrophages were isolated and differentiated from blood mononuclear cells for 7 
days. 104 of each cell types were re-suspended in 80% collagen, 10 % 10x RPMI and 10% 
human serum and adjusted to pH 7.4. The collagen-cell mixture were seeded on a Transwell 
filter insert (1.13 cm2, 0.4 µm pore size) and left for an hour before Caco-2 cells were seeded 
on the top of the layer at a seeding density of 60,000/well. The co-culture was cultivated for 
21 days to allow intact Caco-2 monolayer formation. The barrier formation was monitored 
by Trans-Epithelial Electrical Resistance measurement (TEER) during the course of 
cultivation. After a tight monolayer was obtained, inflammation was induced by addition of 
IL-1ß (10 ng/ml, diluted from a stock solution prepared with 1% BSA in demineralized 
water) for 48 hours. 
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3.3.5 Budesonide formulation testing 
After 48 hours of stimulation, IL-1ß was removed from co-culture and 100 µg/ml 
budesonide in free solution (prepared from a 100 mg/ml stock solution of budesonide in 
ethanol) as well as in PLGA and liposome formulations were added to the apical side of the 
co-culture for 4 hours, giving an effective budesonide concentration of 20 µg/well (Fig. 16). 
At the end of incubation time budesonide formulations were removed and the co-culture 
were used either for Transepithelial Electrical Resistance (TEER) value tracking and IL-8 
sampling or for confocal microscopy imaging. 
 
 
Figure 16. Experimental timeline of setting up the in vitro model of inflamed intestinal mucosa and 
subsequent budesonide formulation testing. 
 
3.3.6 IL-8 cytokine measurement 
Culture medium (50 µl) was removed after 24 and 48 hours and replaced with fresh 
medium. The IL-8 protein content measurement in the cell supernatant was conducted 
according to the manufacturer’s protocol. The supernatant was mixed with 50 µl of CBA 
Flex beads and left for 1 hour before detection beads were added to the mixture and 
incubated for 2 hours without light exposure. The quantification was done via a fluorescent 
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activated cell sorter (FACS Calibur, BD Biosciences, Germany) using FCAP array v1.0.1 
cytometric beat array analysis software.   
 
3.3.7 Transepithelial Electrical Resistance (TEER) measurement 
Transepithelial electrical resistance was measured with STX2 electrode using EVOM2 
(World Precision Instruments, Sarasota, USA). For the measurement, the cells were placed 
on a pre-conditioned 37°C heating plate to avoid the temperature shock-related TEER value 
fluctuation. TEER value was obtained after subtracting the resulting value with the value of 
blank filter in the medium. 
 
3.3.8 Confocal Laser Scanning Microscopy 
Fluorescence images were captured by a Zeiss LSM 510 confocal microscope with the 
software LSM510 package. Z-stack dataset images were captured and reconstructed into 
three-dimensional image using Volocity (Improvisions, Lexington, MA, USA) imaging 
software. 
 
3.3.9 Statistical analysis 
All the experiments were conducted in triplicate and repeated twice for reproducibility. The 
mean values, standard deviations, stand errors and significant differences were calculated 
with ANOVA, Holm-Sidak test using SigmaStat 3.0 software.   
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3.4 Results 
3.4.1 PLGA nanoparticle and liposome characterization 
Both budesonide loaded nanocarrier systems were found to be monodisperse and in the 
same size range of 190 to 220 nm (Table 4). Budesonide encapsulation into FA-PLGA 
nanoparticles did not affect the size of the polymeric particles. Similar sizes were yielded for 
the blank nanocarrier control with a minor variance in polydispersity, which may be 
attributed to variations from batch to batch. A significantly smaller size was observed for 
drug-free liposomal formulation. In comparison with liposomal formulation, PLGA 
nanoparticles demonstrated 10-times higher encapsulation efficiency at 46% of 45 mg of 
drug employed in the particle preparation. The corresponding drug loading capacity for the 
PLGA particles was calculated at 0.07 mg budesonide per mg of FA-PLGA nanoparticles.  
 
Table 4. Physicochemical properties of tested formulations and blank nanocarrier controls. PDI = 
Polydispersity index, EE = Encapsulation efficiency; mean ± SD, n = 3 
 
Formulation Size (nm) PDI E.E. (%) 
Budesonide  solution -- -- -- 
FA-PLGA-budesonide 220 0.1 46 
FA-PLGA- drug free 220 0.06 -- 
Liposomal budesonide 190 0.05 4.2 
Liposomes – drug free 120 0.02 -- 
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3.4.2 TEER value monitoring 
TEER value was monitored during the course of the experiment, starting at induction of 
inflammation up to day 4 of budesonide treatment. It was normalized with regards to the 
untreated non-inflamed control, which showed stable values with normal passage to 
passage variations of absolute TEER in the range of 650 to 800 Ω*cm2 (data not shown) 
during the entire time course of the experiment . In response to stimulation with IL-1ß, a 10 
to 20% drop in TEER was observed after 48 h, indicating successful induction of 
inflammation. IL-1ß was removed at day two and cells were treated immediately with the 
respective budesonide formulation (the time point of treatment being indicated with an 
arrow in figure 17a-c). As shown in figure 17a, the untreated inflamed control showed slow 
recovery after the inflammation, indicated by reduced TEER value of around 12% from day 
2 to day 4 after stimulation. The barrier function was recovered 4 days after removal of IL-
1ß. Budesonide treatment using the free drug solution acted rapidly and normalized the 
TEER value within the first 24 hours after treatment (Fig. 17a). A similar result for rapid 
recovery is also observed from the co-culture treated with PLGA-budesonide formulation, as 
the TEER value reached the level of control TEER value within 24 hours. Although 
budesonide seemed to work effectively in free solution and in PLGA particle formulation, 
budesonide in liposomal formulation worsened the inflammation and impaired the barrier 
function as indicated by the decrease of TEER level to 70% of the control value after the first 
24 hours of treatment. TEER values then settled around 80% 4 days after treatment but did 
not completely recover. In comparison, blank liposomes did not have this impact on the 
barrier integrity (Fig. 17b) and led to a gradual recovery of the TEER value compared to the 
untreated inflamed control. The slow recovery of TEER value was also observed with blank 
PLGA nanocarriers (Fig. 17c). Treatment with both formulations without active compound 
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recovered barrier function 48 h days after treatment, which was slower than the 
formulations with budesonide, but earlier than the untreated inflamed control. 
a) 
 
b) 
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c) 
 
Figure 17. TEER values of triple co-culture model during the stimulation of inflammation and 4 days 
into treatment, normalized to healthy untreated control. Budesonide treatment was conducted 2 days 
after induction of inflammation (arrow). a.) TEER changes after treatment with budesonide in free 
solution, liposome and PLGA formulations, b.) comparison of blank liposomes and liposomal 
budesonide formulation c.)  comparison blank and budesonide loaded FA-PLGA nanoparticles (mean 
± SD, n = 9, significant differences (P < 0.05) and very significant differences (P<0.01) to non- inflamed 
control are indicated with * and ** respectively). 
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3.4.3 IL-8 release rate 
As another marker of inflammation, the IL-8 release of the cells under budesonide treatment 
was measured. The healthy untreated control released around 8 pg/ml*hour IL-8 (data not 
shown). Upon stimulation of inflammation with IL-1ß, increased IL-8 release was observed 
in all experiments with release rates ranging between 20-25 pg/ml*hour 48 h after induction 
of inflammation (Fig. 18). The variance in IL-8 release can be attributed to normal variations 
among different triple culture isolations. At this point, IL-1ß was removed from the cell 
culture and cells were treated with the respective budesonide formulations at a budesonide 
concentration of 100 µg/ml or blank carrier/medium control for 4 hours. Upon removal of 
IL-1ß the medium control showed slight self-healing effects as the IL-8 release dropped to 
around 40% from the initial inflammation level, but was twice as high as the healthy control 
(Fig. 18). Treatment with free budesonide reduced the IL-8 production to 13% of initial 
inflamed value during the course of the first day, which is similar to the levels of the healthy 
control. IL-8 production increased again in the following days, reaching back to 6% of initial 
inflamed value.  
The two liposome formulations with or without budesonide showed the highest IL-8 release 
rate. In the cells treated with blank liposomes, IL-8 production was reduced to 38% of initial 
value after one day corresponding to the values from the non-treated medium control.  
However, the relapse over the next few days was stronger as IL-8 levels reached 75-80% of 
normalized value after 2-4 days. Budesonide loaded liposomes had increased production of 
IL-8 up to 124%  to 156%  of initial value after 24 and 48 hours, respectively, reaching  3 
times higher IL-8 secretion rates than the starting values after 4 days. PLGA formulation 
seemed to be effective in reducing IL-8 release, as PLGA-budesonide particles led to 16% 
decrease of IL-8 during the first 2-days. This decrease indicates a prolonged effect of 
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budesonide compared to the free budesonide formulation, as IL-8 release remained at low 
levels of 19% compared to the healthy control after 4 days of treatment. The blank PLGA 
particles were also observed to reduce the IL-8 level to a fluctuating value of around 30 to 
50% of initial value. 
 
 
 
Figure 18. Normalized IL-8 release rate of triple co-culture model after induction of inflammation and 
treatment effects of various budesonide formulations and blank nanocarrier controls. (mean ± SD, n = 
9, *= significant difference to healthy untreated control (P < 0.05),  **= very significant difference to 
healthy untreated control (P < 0.01)) 
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3.4.4 Deposition of drug carrier systems 
For confocal laser scanning microscopy experiments, nanocarrier systems were fluorescently 
labeled by covalent coupling of fluorescein to PLGA [115] and by rhodamine to the 
liposomal lipid.  For easier recognition, the red rhodamine signal was translated to green 
signal in the images displayed. The fluorescence microscopy pictures revealed the 
deposition of liposomes and PLGA budesonide particles throughout the healthy and 
inflamed in vitro model. In both the healthy and inflamed triple culture setup, only low 
amounts of PLGA budesonide particles were observed to adhere to the apical surface (Fig. 
19a&c). Contrastingly, in the inflamed model, the particles were found in the junctional 
space of the monolayer and no co-localization with immunocompetent cells was observed 
(Fig. 19c). The liposomes were deposited on the surface and to some extent into the 
basolateral layer of the healthy model (Fig. 19b). A deeper penetration of the liposomes was 
observed in the inflamed model, in which the fluorescent signals were primarily found in 
the basolateral side of the model (Fig. 19d). In both healthy and inflamed models, some but 
not exclusively all rhodamine signals from the liposome was found in co-localization with 
auto-fluorescence signal of immunocompetent cells (Fig. 19b&d). Furthermore, the 
rhodamine signal appeared more diffuse and spread out, indicating at a break down or 
processing of the liposomes. 
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a) 
      
b) 
 
  
 
c) 
 
d) 
 
  
Figure 19. Deposition of budesonide loaded FA-PLGA nanoparticles (a.&c.) and liposomal 
budesonide (b.&d.)-in the triple co-culture model of the intestinal mucosa in non-inflamed state 
(a.&b.) and after successful induction of inflammation (c.&d.) as observed by confocal laser scanning 
microscopy;  blue signal: Caco-2 cell nuclei stained with DAPI, red signal: autofluorescence of  
immunocompetent cells; green signal: fluorescence labeled nanoformulations (red).  
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3.5 Discussion 
As reported previously, a novel in vitro model of the inflamed intestinal mucosa was 
established and characterized in our laboratory [105]. To further evaluate the power of the in 
vitro model in the context of pharmacology (formulation development and drug delivery 
research), two different carrier systems (a PLGA polymeric nanoparticle system and a 
liposomal system) loaded with the glucocorticoid budesonide were evaluated in the system. 
Both therapeutic efficacy and the mechanism of uptake and action for the two nanocarrier 
systems were tested in the in vitro model. 
Nanocarrier systems have been extensively used in drug delivery applications due to their 
ability in controlled release and to actively or passively target the site of action. With regards 
to IBD treatments, nanocarriers were previously proven in different animal colitis models to 
accumulate passively in inflamed intestinal areas forming a drug depot for encapsulated 
compounds and thus improving anti-inflammatory therapy and reducing systemic adverse 
effects [118].  Both PLGA polymeric nanoparticles and liposomes are widely used in the field 
of nanomedicine for their easy-to-handle manner and their biodegradability. PLGA 
polymers are degraded in the body to their components through hydrolysis of the ester-
bonds to lactic acid and glycolic acid. These molecules are further metabolized in the citric 
acid cycle, contributing to their biocompatibility and low toxicity. PLGA nanocarriers have 
previously been investigated for application in IBD as delivery systems for 5-aminosalicylic 
acid and tacrolimus and after chitosan surface modification for localized delivery of nuclear 
factor kappa decoy oligonucleotide [119]. To increase the stability in low pH and target the 
drug release to the distal ileum and colon, PLGA can also be blended with Eudragit S100 
[116, 120]. 
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Although some studies showed the potential of liposomes for oral drug delivery, their 
stability in the low pH and enzyme-rich environment of the gastrointestinal tract presents a 
significant issue. To target the inflamed intestinal mucosa from the luminal side, liposomes 
have to be applied rectally as enemas, avoiding the stressful gut passage and issues of 
stability and coalescence. The intravenous pathway is more common for liposome 
applications, in which they passively accumulate via endothelium fenestrations in inflamed 
areas. Stealth liposomal formulations as employed in this study are known to escape 
opsonization and uptake by reticuloendothelial system, and thereby increasing their 
circulation half-life and extravasation likelihood [121]. 
Both carrier systems are known to be “Trojan horses” for poorly soluble hydrophobic 
compounds, such as budesonide. In this study, budesonide was incorporated into the 
hydrophobic core of the PLGA nanoparticles and within the liposomes, thus increasing the 
apparent solubility and bioavailability. Encapsulation efficiency for budesonide in liposome 
was about 10-times lower compared to FA-PLGA nanoparticles which presented an ideal 
matrix for incorporation of small hydrophobic compounds with an encapsulation efficiency 
of 46% and a drug loading rate of 7%. It is to be noted that the fluorescence labeling of the 
polymer by covalent linking of fluorescein to the 50:50 PLGA polymer for detection in the 
confocal microscopy study led to a more hydrophilic derivative and reduced the drug 
loading capacity compared to the native polymer. The native polymer was found to 
accommodate up to 14% of budesonide drug in line with previous glucocorticoid PLGA 
formulations (data not shown). For the in vitro studies, the differences in drug loading 
between the two evaluated formulations were compensated by normalizing the amount of 
the respective formulation. The total budesonide dose was 100 µg/ml single application for 
each formulation to reach a comparable effect in the order of magnitude to the daily dosage 
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of Entocort® EC of 36µg/ml in intestinal fluid. The incubation time in the model was settled 
for 4 hours to approximate drug retention time in the intestine of IBD patients. 
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Figure 20. In vitro release of budesonide from PLGA nanoparticles in phosphate buffered saline pH 
6.8 and co-culture apical medium (DMEM, 10%FCS, 1% nonessential amino acid, 1% Pen/Strep pH 
7.2) (n=3).   
 
At the site of action, drug release from non-coated PLGA nanoparticles is a two-step process 
with an initial burst release of drug adsorbed to the particle surface or bound in the outer 
layer of particle followed by a slower continuous release mediated by a combination of 
compound diffusion out nanopores and -channels and polymer degradation [122].  Under 
sink conditions, the budesonide burst release from FA-PLGA nanoparticles in this study was 
found to be 42% in the first 4 h, leaving almost 60% of encapsulated drug to form a drug 
depot at the target site (Fig. 20). Although previously known that stealth liposomes are able 
to escape from reticuloendothelial system when delivered from the blood side, the 
liposomes in our study seemed to be internalized and degraded by activated intestinal 
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immunocompetent cells, leading to an area-concentrated burst release after application from 
apical side of the intestinal model [117]. 
In our study, TEER values were decreased upon induction of inflammation in the co-culture 
model. Epithelial barrier integrity was disrupted due to tight junctional re-organization. Free 
budesonide showed a strong anti-inflammatory effect by immediately recovering the TEER 
value and reducing the IL-8 release in the model (Fig. 17a). PLGA-budesonide nanoparticles 
showed a similar anti-inflammatory effect. The results from IL-8 analysis, however, revealed 
the longevity of the PLGA treatment effect (Fig. 18). In the cells treated with free budesonide 
solution, we observed an immediate decrease of IL-8 production within the first 24 hours of 
treatment. The effect did not last long and the release rate rebounded and increased after the 
second day to 4th day, which fits with the in vivo dosing scheme of free budesonide that is 
renewed daily [97]. Meanwhile, PLGA-budesonide dispersion reduced the IL-8 release 
levels almost to the levels from the healthy control and maintained it throughout the 
experimental duration of 4 days (Fig. 18).  
A slight carrier effect was observed in the control experiments as cells treated with drug free 
PLGA nanoparticles, as well as, blank liposomes showed a faster recovery of barrier 
properties compared to control (Fig. 17b&c). In addition, blank PLGA nanoparticles 
significantly reduced IL-8 inflammation marker levels after 24 h and 48 h of treatment 
(Fig. 18). This phenomenon may be related to blank particle interaction with immune cells in 
the triple culture leading to a pre-occupation of the immune system with this new stimulus. 
However, low probing and internalization of PLGA nanocarriers by immunocompetent cells 
were observed by confocal images. Alternatively, an adsorption of soluble signaling 
parameters in the inflammatory cascade of IL-8 to the particle surface might explain the 
findings.  
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The proposed hypothesis of a prolonged activity of PLGA-budesonide nanoparticles due to 
depot formation and prolonged budesonide release is supported by the findings from the 
confocal microscopy study. Epithelial barrier function was disrupted and slightly loosened 
up in the inflamed model, allowing the PLGA nanoparticles to accumulate in the space 
between the cells but not translocated to the basolateral side. This effect was not observed in 
the healthy model where almost no particles were adhering to the apical side or 
accumulated in the intercellular space. The PLGA nanoparticles at 220 nm size were retained 
in the upper region of the tight junctions since they are bigger than the tight junctional pore 
of 58 to 104 nm [123]. The inflammation of the cell model leads to a broadening of 
intercellular space where the nanoparticles are trapped, while not allowing to difuse to the 
basolateral side. This differs from our previous observation with Fluoresbrite® nanoparticles, 
in which the particles were deposited on the top of the monolayer or internalized by 
activated immunocompetent cells [105]. Those particles were, however, rigid polystyrene 
particles and not biodegradable. Therefore, they were developed as model particles without 
concerns about drug delivery properties.  
As reported in several publications, fluorescent dye in labeled nanocarriers may leak or be 
dissociated from the nanocarriers [124, 125], giving erroneous particle uptake and 
distribution data. The dissociation of fluorescein is unlikely in this study as the dye was 
covalently bound to the PLGA polymers and previously shown to not diffuse out of the 
PLGA nanoparticles [117].  
In contrast to the PLGA nanoparticles, the liposomal formulation did worsen the 
inflammation by disrupting the barrier integrity and increasing the IL-8 release of the cells. 
(Fig. 17a&b, Fig. 18). The resulting epithelial defects are clearly detectable by confocal 
images of the liposome treated 3D model as irregular large areas with DAPI stained nuclei 
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(Fig. 19d). The loosening and rupture of the epithelial barrier resulted in transversing 
liposomes, which were then directly exposed to immunocompetent cells in the basolateral 
side (Fig. 19d). In our study, the rhodamine dye was incorporated into the liposome via 
covalent binding to the lipid (1,2-dipalmitoyl-sn-glycero-3-phosphoethanolaine-N-
(Lissamine rhodamine B Sulfonyl). This coupling ensured that the fluorescence signal 
detected is mostly from the lipid. It does not, however, warrant the integrity of the 
liposomes. From the diffuse signal in the confocal images and the deposition of the 
fluorescence signal, it is observed that the lipids may have been dissociated and the 
liposome itself broken down. This effect is not associated to the liposome carrier itself but 
more to the specific liposomal budesonide formulation. The unloaded liposomes slightly 
increased the IL-8 release. In contrast, budesonide liposome formulation showed a 
significantly higher IL-8 release from the initial release in inflamed cells (Fig. 18). Therefore 
the toxicity is likely not associated to a formulation component or the liposome 
concentration (which is 10-fold higher compared to the PLGA nanoparticles to compensate 
for the lower loading capacity).  The toxicity is caused by the sudden budesonide release in 
the basolateral side as a consequence of liposome uptake and disruption by phagocytic cells. 
The evaluated liposomal budesonide formulation at the concentration used in this study is 
thus not applicable for IBD treatment.  
These results are in agreement with a previous study performed, in which a similar 
glucocorticoid (dexamethasone) in liposomal formulation seemed to aggravate the disease in 
a DSS mouse model of colitis. In contrast, the same dexamethasone formulation improved 
the condition in multiple sclerosis animal models [112]. The authors hypothesize that 
preferential uptake into tissue macrophages and shifting of macrophage may account for the 
differences observed.  In the intestine, the M1 macrophage phenotype may be essential to 
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keep up innate immune answer preventing pathogen invasion across the barrier and in the 
same time tolerating commensal intestinal flora. However, direct uptake of glucocorticoid 
tends to shift the macrophage population to a more anti-inflammatory M2 characteristic, 
leading to more aberrant activation of immune system. Thus anti-inflammatory therapy in 
epithelial cells and dendritic cells may be beneficial for IBD treatment while interference 
with macrophage function should be avoided. For successful application in IBD treatment, 
liposomes do not only have to withstand diverse physiological condition found in GI tract 
but also have to be specifically directed to inflamed area of the intestine. Jubeh et al. 
reported the significance of charge properties for the liposome adhesion behavior [126]. 
Anionic liposomes were found augmented in inflamed area of rat intestine while cationic or 
neutral liposomes were accumulating in healthy tissue. The negative charge of the liposome 
used in this study may promote the adhesion to inflamed tissue, but the uptake by 
phagocytic macrophages seemed to particularly worsening the inflammation. 
In summary, PLGA-budesonide formulation was found to be superior in this study, 
compared to both free budesonide solution and liposome formulation. As the first drug-
loaded nanocarriers tested in the triple co-culture model, the particles showed an 
advantageous properties and good efficacy for recovery from inflammation as indicated by 
TEER value and pro-inflammatory protein release. This formulation also showed evidence 
of depot effect for budesonide release. Another advantage is the higher encapsulation 
efficiency of PLGA particles in comparison to the liposome. This avoids a higher loss of 
budesonide in the generation of the formulation. The PLGA particles did not adhere to the 
healthy model nor were they translocated to the basolateral side, showing their ability to 
avoid preemptive absorption in the upper non-affected parts of the gastro-intestinal tract 
and thus systemic exposure.  Instead, they specifically adhere to the more mucus rich and 
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acidic inflamed model tissue also commonly found in IBD patients [127]. Furthermore, the 
loosening of tight junctional complexes increases their chance to reach and accumulate in the 
targeted inflammation area. Budesonide loaded liposomes at the concentration studied were 
proven to be toxic to the inflamed tissue, which was likely due to the instant release of 
budesonide after the uptake by immunocompetent cells. The effect of this dose dump is 
thought to be more pronounced for the liposomes compared to the free drug solution, as the 
majority of the budesonide dose is localized to the immune cells instead of being equally 
distributed among all three cell types in the triple culture. In conclusion, a smaller dosage of 
liposomes or lower budesonide loading might be more preferential for localized IBD 
treatment. 
Several cell culture models have been developed incorporating immunocompetent cells, 
such as macrophages or B-cells, to simulate intestinal tissue [15, 20, 128]. In our model, 
inflammatory response is promoted by addition of pro-inflammatory cytokine to triple 
culture of epithelial and immunocompetent cells to mimic the inflammation in IBD. This 
model is able to reflect the long-term recovery process after controlled inflammation, while 
it can be used to study mechanism of carrier uptake in a complex system. Macrophages and 
dendritic cells were in direct contact with the epithelial cells, allowing the monitoring and 
tracking of carrier deposition and further processing in the inflamed intestinal tissue. 
The superiority of the triple co-culture model compared to conventional cell culture models 
has been underlined in this study [105]. Different read out parameters could be used to 
evaluate the treatment efficacy and the experimental setup gives better representation of 
pathophysiological changes in IBD compared to Caco-2 cells alone. In particular, the 
involvement of immune cells for the inflammatory response is essential, giving significantly 
higher inflammatory marker release compared to the respective monocultures. This 
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interplay seems to exist between all three cell types in the co-culture model, as only the 
presence of both dendritic cells and macrophages synergistically enhanced the strength of 
the immune answer, as shown previously [105]. Also, a preferential uptake of nanoparticles 
and other foreign objects into immune cells was observed. As we are not able to differentiate 
between both immune cell types by direct antibody staining due to embedding in the 
collagen layer, it is not possible to state which immune cell type does the majority of 
nanoparticle or liposome processing. However, previous studies in a triple culture model of 
the alveolar mucosa found a preferential uptake by monocyte derived macrophages which 
then passed on the particulate cargo to the dendritic cells for further antigen processing and 
induction of immune answer [129].  
In conclusion, testing in this advanced in vitro model should allow us to study the drug and 
formulation effect on the epithelial barrier as well as on the innate immune system. The 
model was found to be powerful for the screening of suitable anti-inflammatory 
formulations and drugs as a pre-stage for in vivo animal studies. Thereby the number of 
animal tests can be reduced, lessening the ethical burden and speeding up the screening 
process and the development of novel IBD therapies.  
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4. SIMPLI-Well: A novel cell culture system based on ultrathin silicon 
nitride (Si3N4) porous supports for transport and translocation 
studies  
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4.1 Abstract 
Nanoparticles are being intensively investigated for their toxicity as well as their use as drug 
delivery vehicles. In this context, a tool for studying particle translocation across different 
biological barriers is crucial. Conventional polyester/polycarbonate-based filter inserts have 
been reliably used for transport studies of drug-like compounds and other small molecules 
as they present only a negligible barrier for low molecular-weight substances. 
However, the filters pose a significant hindrance to the translocation of macromolecules and 
nanoparticles due to the thickness of the permeable substrate (typically 10 µm), which leads 
to an underestimation of particle translocation. Therefore we propose a novel SIMPLI 
(Silicon Microporous PermeabLe Insert)-Well system as an alternative two compartment 
setup. The SIMPLI-Well accommodates a porous support made in silicon nitride with 
greatly reduced thickness (500 nm) and higher pore density (15 or 20%) compared to 
commercial inserts. These physical features essentially remove the hindrance to 
(nano)particle translocation. Here, the SIMPLI-Well system was characterized with regards 
to proliferation, differentiation and functionality of the intestinal epithelial cell line, Caco-2. 
The formation of tight junctions was studied as well as the transport behaviour of the high 
permeability marker propranolol and low permeability marker sodium fluorescein. The 
transport of 50 nm polystyrene nanoparticles was also investigated to validate the system as 
suitable for the study of Caco-2/nanoparticle interactions. Results were compared with 
those of cells grown on conventional polymer based filter inserts. The SIMPLI-Well was 
found to be a good growth support for Caco-2 cells, allowing the cells to form confluent 
monolayers with appropriate transepithelial electrical resistance (TEER) values. The overall 
transport across the SIMPLI-Well was increased compared to commercial inserts and the 
system was able to differentiate between paracellularly and transcellularly transported 
compounds. In addition, the reduced thickness of the porous support in the novel device 
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allowed 50 nm polystyrene particles to translocate, thus demonstrating the potential of the 
system for nanotoxicology studies and pharmacokinetic testing of nanomedicines. 
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4.2 Introduction 
Predicting the permeability of a molecule and thus its ability to be absorbed into the body is 
crucial for the pharmaceutical development of drug candidates. Permeability studies have 
been mostly conducted using epithelial cell monolayers grown to confluence on porous 
poly-ester/-carbonate filter inserts. These inserts are suspended in a standard multi-well 
plate where they form distinct apical and basolateral compartments separated by the 
permeable polymer filter.  
Absorption and permeability can be studied in this setup, as it is assumed that diffusion 
across a monolayer of epithelial cells is the rate limiting step in the transport process with 
the permeable polymer filter providing only growth support and mechanical stability. This 
correlates to the fact that the monolayer of enterocytes is the principal barrier for drug 
absorption after oral application in vivo [1]. 
Caco-2 is the most relevant model for the intestinal mucosa. Data obtained from drug 
transport behavior across confluent Caco-2 cell monolayers has been found to correlate 
directly to data from oral drug absorption in humans [130]. Thus the Caco-2 in vitro model 
has become the most widely spread permeability model and has been validated for the use 
in the BCS (Biopharmaceutics Classification System) of active pharmaceutical substances 
(API), directly affecting drug regulatory processes via the so called biowaiver[11]. 
Various other immortalized or human cancer originated cell lines have been used as models 
for other epithelial barriers e.g. Calu-3 [131] or 16HBE14o- [132] for the bronchial mucosa. 
As a general feature, all of these cell lines differentiate to monolayers after confluence and 
form tight junctions to build a more or less tight barrier regulating absorption and secretion. 
They quite adequately mimic the in vivo situation also with regards to phenotypic 
expression of drug transporters and metabolizing enzymes. Thus it is possible to distinguish 
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between different compounds with regards to their preferred transport pathway across a 
certain epithelium – for example, transcellular transport of small hydrophobic molecules 
and paracellular transport of hydrophilic solutes - and to investigate drug- transporter 
interactions [133]. 
Apart from investigations on drug compounds alone, the interaction of more complex 
formulations of drugs and excipients with the respective epithelial barrier is also of interest. 
Formulations may range from simple physical mixtures of different compounds to complex 
and smart drug carriers [134, 135]. Excipients can modulate barrier properties, the activity of 
drug transporters and metabolizing enzymes and the transport pathways of a compound 
[136]. Nanoscaled drug carrier systems such as polymeric particles or liposomal 
formulations are of particular interest in pharmaceutical technology as they can selectively 
target their cargo molecules to their site of action [137]. 
On the other hand, novel nanotechnology based approaches also present risks to patients 
and consumers. Non-biodegradable, engineered nanoparticles such as metal and metal 
oxide particles are employed in paints, surface coatings and various high tech products 
[138]. In vivo findings of translocation of the ultrafine particles from environmental pollution 
across the lung barrier [139] into human systemic circulation and across the blood-brain 
barrier into the brain [140] have raised awareness of these particles and associated risks. 
Thus the hazard, risk and toxicology of particulate air pollutants and industrially fabricated 
nanoparticles have been and continue to be intensively studied [141].  
Increasing evidence is emerging that the conventional polymer-based commercial inserts 
may not be suitable for the study of particle translocation. For example, particles have been 
reported to be able to breach the in vivo barrier of the gastrointestinal tract [142] or the lungs 
and nanoparticles have been found in the liver, lungs, heart, kidney, spleen, brain [143].  
However, in vitro translocation studies of these particles using standard setups have shown 
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tremendously low rate of transport and led to underestimated values of translocation 
compared to in vivo situation [144, 145].  
The main reason for the low permeability of nanoparticles across polyester/-carbonate 
inserts is the filter thickness which is typically over 10 µm. The thickness contributes to low 
permeability in three ways. Firstly, the reduction of the thickness of the filters by a factor of 
20 will reduce the time needed to cross the filter by a factor of 20. Secondly, adsorption of 
the species under study may take place on the internal surfaces of the filter i.e. in the pores. 
This surface area increases linearly with the thickness of the filter. Finally, adsorption of 
large species to the internal (pore) surfaces of the filter may not only remove the species 
from the experiment but also block the pores. A new porous support for the study of 
nanoparticle transport should therefore be as thin as is feasible  
 
Silicon nitride (Si3N4) is a hard ceramic with exceptional toughness (for a ceramic) and 
chemical resistance.  It is used in biomedical implants because of its robustness, and 
biocompatibility [146] Silicon nitride surfaces have served successfully as cell growth 
supports [147-149]. Using standard silicon microfabrication techniques it is possible to 
produce free-standing ultrathin (~500nm) microporous membranes of low-stress silicon 
nitride in a silicon ‘frame’. A similar porous membrane support has been reported before for 
observation of cell-cell contacts in a blood-brain barrier model [150]. In this paper we 
expand the use of these ultrathin silicon nitride supports (in combination with a dedicated 
holder) to nanoparticle and macromolecule transport studies. When fitted in the holder, the 
porous support can be suspended in a multiwell plate to form a two-compartment system in 
which apical and basolateral compartments are separated by a porous support that is only 
500nm thick.  We have named this the Silicon Microporous PermeabLe Insert) or SIMPLI-
Well system. 
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This paper describes a characterisation of the SIMPLI-well system as a cell growth support, 
particularly focussing on cell differentiation and the formation of tight junctions on the 
example of the Caco-2 cell line. The system’s molecular transport properties were 
investigated using classical transcellular and paracellular markers. Finally we studied its use 
in nanoparticle translocation experiments using 50 nm sized polystyrene beads as model 
particles.  
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4.3 Material and Methods 
4.3.1 Materials 
Fluoresbrite® carboxylated nanoparticles 50 nm in diameter were purchased from 
Polysciences (Warrington, PA, USA). The human colon adenocarcinoma cell line Caco-2 
clone C2Bbe1 was obtained from the American Type Culture Collection (Rockville, MD). 
Dulbecco’s modified Eagle’s medium (DMEM), foetal calf serum, non-essential amino acids 
and Phosphate buffered saline (PBS) were purchased from PAA (Pasching, Austria). 
Trypsin/EDTA was obtained from Sigma (Steinheim, Germany). Plastic dishes and plates 
were obtained from Greiner Bio-One, Transwell inserts with pore sizes 0.4 µm and 3 µm 
were purchased from Corning Incorporated (Acton, MA, USA), and with pore sizes of 0.4, 1 
and 3 µm were obtained from BD Biosciences (Heidelberg, Germany). 4, 6-Diamidino-2-
phenylindol, Fluorescein sodium salt (FluNa) and organic solvents were acquired from 
Sigma (Steinheim, Germany). Rabbit anti-ZO-1 antibody was obtained from Zymed 
Laboratories Inc (San Francisco, CA, USA) and Alexa Fluor 568 labelled goat-anti rabbit 
secondary antibody was purchased from BD (Heidelberg, Germany). FluorsafeTM for sample 
mounting was obtained from Calbiochem (San Diego, USA).  Polyaryl ether ether ketone 
(Ketron ® PEEK-1000) was purchased from Angst & Pfister (Zurich, Switzerland) 
 
4.3.2 Design and fabrication of the Silicon Microporous PermeabLe Insert (SIMPLI) -
Well system 
The SIMPLI-Well holder was machined in Polyether ether ketone (PEEK) due to its excellent 
mechanical and chemical resistance even at high temperatures, which allows sterilisation by 
autoclaving. The porous supports for cell culture are fabricated using a standard 
microfabrication process [151, 152]. Briefly, 500 nm of low stress (non-stoichiometric) silicon 
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nitride (Si3N4) is deposited on both sides of a 380 µm thick silicon wafer by low pressure 
chemical vapour deposition (LPCVD). Photolithography defines structures on both sides of 
the wafer that are etched into the silicon nitride by reactive ion etching (RIE). The structures 
on the top side define the pore size, shape, and period in the porous support. On the other 
side of the wafer, square openings in the silicon nitride are used as a mask for a wet KOH 
etch that removes the exposed silicon and releases the porous silicon nitride supports as 
microporous membranes 1 x 1 mm in size. The silicon wafer was then diced into 14 x 14 mm 
chips each of which had 23 porous membranes.  
The combination of the PEEK holder with the 14 x 14 mm silicon nitride chips allowed the 
use of the porous supports in a standard 6-well cell culture plate.  
 
4.3.3 Pre-treatment and regeneration of silicon nitride porous supports  
After fabrication, the porous supports were cleaned with Piranha Solution (H2SO4 98% and 
H2O2 30%, in a 4:1 ratio) at 110°C, extensively rinsed with water and dried at room 
temperature. They could then be stored in Milli-Q water for a few days till use. Alternatively 
they were dried and cleaned with SC1 solution NH4OH 24%, H2O2 30% and deionized water 
H2O2, in 1:1:5 ratio) at 70°C followed by extensive rinsing with water and drying at room 
temperature just prior to use. The porous supports were immersed in cell culture medium 
for at least 30 minutes before cell seeding. After cell growth the supports were cleaned using 
Piranha solution and re-used.  
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4.3.4 Cell culture 
Caco-2 clone C2Bbe1 (passage 65-78) were passaged and cultured with a seeding density of 
6*104 cells/cm2 in the 6 well inserts from Corning and BD and the SIMPLI-Well system. For 
the geometrical characteristics of the supports used in this study see table 5. The cells were 
fed with culture medium composed of DMEM, 10% FCS and 1% non-essential amino acid 
and maintained at 37°C in a 5% CO2 and 95% humidity environment. TEER was measured 
every other day with Epithelial Voltohmmeter (World Precision Instruments, Sarasota, US) 
and the medium was changed directly afterwards. 
 
Table 5. Geometrical characteristics of membranes used in the study 
 Pore diameter 
 
 (µm) 
Pore density 
 
 (*106 cm-2) 
Filter area 
 
(cm2) 
Total pore 
area/filter 
(*106 µm2) 
Pore area 
/filter  
(%) 
Corning 0.4 4.0 1.12 0.45 0.4 
3 2.0 1.12 15.83 14.1 
BD Falcon 0.4 2.0 0.90 0.23 0.3 
1 1.6 0.90 1.13 1.3 
3 0.8 0.90 5.09 5.7 
Si3N4  - 
SIMPLI-Well 
2 6.5 0.23 4.60 20.0 
1 19.1 0.23 3.45 15.0 
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4.3.5 Permeability of fluorescein, propranolol and nanoparticles on blank and cell 
grown filter 
Either 10 mg/ml sodium fluorescein or propranolol was dissolved in Krebs-Ringer buffer 
(KRB) and added to the apical side of the insert. For nanoparticle translocation experiments, 
0.1% (1.5 x 1013 particles/ml) of 50 nm Fluoresbrite® carboxylated nanoparticles were 
suspended in 1% BSA in KRB buffer to prevent aggregation and added to the apical 
compartment. Transport buffer was added to the basolateral compartment and the setup 
was put on an orbital shaker at 150 rpm in the incubator. For the cell-free set up, samples 
were taken every 2 minutes for the first 10 minutes and at 10 minutes intervals up to 1 hour. 
Samples of translocated compounds and nanoparticles in cell-covered system were taken 
every 30 minutes up to 4 hours. In case of the polystyrene beads the duration of the 
transport experiment was extended to 24 h. Transported sodium fluorescein and fluoresbrite 
particle was measured with a Tecan Infinite 200 Reader at an excitation wavelength of 488 
nm and emission wavelength of 530 nm. Propranolol concentration was measured with an 
Ultimate 3000 HPLC (Dionex) and analysed with Chromeleon software. 
Apparent permeabilities (Papp) were calculated according to the equation: 
Papp = (dQ/dt)*(1/A)*(1/C0)         (eq 2) 
 
Where dQ/dt is the amount of drug transported per time, A is the surface area of the 
monolayer and C0 is initial concentration. 
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4.3.6 Immunohistological staining and Confocal Laser Scanning Microscopy 
Caco-2 cells were fixed with ice-cold ethanol for 30 minutes and stained for ZO-1 expression. 
Samples were incubated with 2.5 µg/ml rabbit-anti human ZO-1 antibody dissolved in 1.5% 
Bovin Serum Albumin (BSA) in phosphate buffered saline (PBS) solution for 1 hour at 37°C 
and later washed with PBS before 1 hour incubation with a second goat rhodamine-anti 
rabbit antibody at the same temperature. Cell nuclei were stained by incubation with DAPI 
for 15 minutes at room temperature. Confocal images were captured with a Zeiss LSM 510 
microscope with LSM510 software package.  
 
4.3.7 Scanning Electron Microscopy 
Cells were fixed in a 2.5% glutaraldehyde in 0.2M cacodylate buffer (pH 7.4) overnight. 
Following this the cells were dehydrated in a series of ethanol/water mixtures: 20%, 30%, 
40%, 50%, 60%, 70%, 80%, 90%, 100% (5 minutes each incubation), followed by critical point 
drying. The sample was then sputtered with 20nm of gold on both sides twice.  
 
4.3.8 Transmission Electron Microscopy 
Cells were fixed in 2.5% glutaraldehyde in 0.2M cacodylate buffer (pH 7.4) overnight. The 
samples were then rinsed in PBS and treated with 1% Osmium tetroxide in 0.1M sodium 
cacodylate buffer (pH7.4) adjusted to 350mosm with NaCl for 2 hour at 4°C. Samples were 
then rinsed with 0.05M sodium maleate buffer (0.05M Maleic acid adjusted to pH5 with 
concentrated NaOH) 3 times for 5 minutes each time. Following this the samples were 
blockstained with 0.5 uranyl acetate in the sodium maleate buffer for 2 hours at 4°C and 
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rinsed with the sodium maleate buffer again (3x5mins). Samples were dehydrated in a series 
of ethanol/water mixtures: 70%, 80%, 90% for 15 minutes per dilution and then in 100% 
ethanol 3 times for ten minutes each step. Finally samples were left in a propylene oxide: 
EPON 1:1 mixture for embedding and left for 5 days at 60 degrees C and then the samples 
were cut 
 
4.3.9 Statistical analysis 
All the experiments were conducted in triplicate for reproducibility. The mean values, 
standard deviations, stand errors and significant differences were calculated with ANOVA, 
Holm-Sidak test using SigmaStat 3.0 software.  
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4.4 Results 
4.4.1 SIMPLI-Well  
The SIMPLI-Well is a clamping system which allows extremely thin microfabricated porous 
supports to be used in the same way as regular polymer inserts (Fig. 21a&b). When the 
SIMPLI-Well is placed in a 6 well plate, the porous support is approximately 1.5 mm from 
the bottom of the well plate to allow for observation by light microscopy. The system has 
been designed in order to have two distinct compartments. This allows for the in vitro 
characterisation of biological barriers, for the investigation of transport properties and for 
TEER measurements to be taken. To ensure that upon cell confluency molecule and/or 
particle transport takes place exclusively through the porous area, it is essential that the 
mechanical tightness of the SIMPLI-well is ensured. This is achieved by clamping the porous 
support via a bayonet system that allows the inner and outer cylinder to slide into each 
other (Fig. 21a). In order to lessen the wear generated by the bayonet movement, a thin 
Teflon O-ring is placed between the chip and the outer cylinder. A silicon O-ring is inserted 
into the bottom of the inner cylinder. This comes into contact with the silicon nitride porous 
support to form a watertight seal and create the apical chamber of the SIMPLI-well. A 
groove has been included in the inner cylinder. This is used for addition and removal of cell 
culture media and for inserting STX2 electrodes for TEER measurements without touching 
the delicate silicon nitride porous support. All the components of the SIMPLI-well can be 
sterilised using a standard laboratory autoclave. The silicon nitride porous support can be 
re-used after cleaning with piranha water. The remaining components can be cleaned in an 
ultrasound bath. The final result is an insert with a distinct apical and basolateral 
compartment that accommodates a rigid ultra-thin silicon nitride porous support whilst still 
allowing for the use of routine laboratory practices.  
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4.4.2 Silicon nitride chip 
Each porous support chip has an area of about 2cm2 and has 23 porous pads each with an 
area of 1mm2 to give a total porous area of 23mm2 (Fig. 22a). The silicon nitride porous areas 
are 0.5µm thick and are ideal for light microscopy studies due to its high transparency 
(Fig. 22a). They are also suitable for Scanning Electron Microscopy (SEM), Transmission 
Electron Microscopy (TEM) and fluorescence microscopy.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21. A An exploded view of the SIMPLI-Well showing all the components that make it up; (a) 
the upper cylinder which clamps into the lower support (e) to create the apical well; (b) a rubber o-
ring to ensure a watertight seal, (c) the silicon nitride porous support, (d) a Teflon o-ring to minimize 
frictional forces generated by the bayonet movement; (e) the lower support which sits suspended in 
the well plate. B A photo of the SIMPLI-Well.  
 
a 
 b 
 
C 
 
d 
 
A 
e 
 
B 
 
Figure 22. a) Image of the SIMPLI-Well silicon nitride porous support; b) SEM image of the 1µm 
pores in a hexagonal arrangement; c)  SEM image of the 500nm thick silicon nitride porous support 
cross section.  
 
a) c) b)
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4.4.3 Epithelial cell growth and differentiation 
Caco-2 cells were seeded on 1 and 2 µm SIMPLI-Well membranes and cell proliferation and 
differentiation was monitored via light microscopy and TEER measurement over 28 days. 
Polyester cell culture inserts from Corning (0.4 µm pore size) and BD (1 µm pore size) were 
used for comparison. A seeding density of 6*104 cells/cm2 was used for all setups. 
Cells grown on silicon nitride porous supports showed slightly slower cell proliferation but 
were able to reach confluency after 14 days, compared to the 8-10 days’ time span needed 
for cells grown on conventional supports. The slower development on SIMPLI-Well is 
mirrored in the TEER values which reached a plateau after 25 days compared to 16-18 days 
for cells grown on polyester insert. The absolute resistance values measured for Caco-2 
monolayers in the SIMPLI-Well was ~2000 Ω (Fig. 23a).  This value has to be adjusted for 
TEER by subtracting the background resistance and multiplying by the filter area. The TEER 
was lowest for the Caco-2 cells on 1µm pore size SIMPLI-Well, followed by the 2 µm pore 
size SIMPLI-Well which peaked at ~300 Ω*cm2.TheTEER values measured in the SIMPLI-
well were significantly lower than for cells grown on Corning or BD inserts which displayed 
values of 450 to 500 Ω*cm2. 
 
 
 
 
 
 
 
 
Figure 23. a) Normalized TEER measurements of Caco-2 cells grown on SIMPLI-Well and polyester 
inserts. Mean ± SD; n = 6-9 b) Expression of tight junction protein ZO-1 in Caco-2 cells grown on 
silicon nitride inserts c) Expression of ZO-1on polyester inserts- Scale bars are 5 µm.  
a 
 
b 
 
c 
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4.4.4 Confocal and SEM analysis 
Cells were characterised by electron microscopy and immunostaining of the tight junction 
protein ZO-1 after maximum TEER values were observed. 
Confocal laser microscopy showed continuous ZO-1 expression at the cell junctions for cells 
grown on 1 µm pore SIMPLI-Well and on commercial inserts (Fig. 23b&c). The ZO-1 signal 
in cells on 2 µm pore SIMPLI-Well was discontinuous (data not shown). A higher 
fluorescence signal intensity was observed on cells grown on polyester inserts than on cells 
grown on 1 µm SIMPLI-wells.  
However, mRNA quantification of ZO-1 expression by real time PCR did not identify any 
statistically significant differences between the different supports (data not shown).  
Observing a mature monolayer of Caco-2 cells by SEM and TEM showed that a 
differentiated monolayer of cells could be seen with functional microvilli regardless of the 
type of support used (Fig. 24a&b). Cells grown on 2 µm SIMPLI-Wells formed a secondary 
layer of cells on the basolateral side, while for 1 µm pore size only parts of cell cytoplasm 
reached across the porous support. No nuclei were found on the basolateral side showing 
that cell migration did not occur (Fig. 24c). 
 
 
 
 
 
 
 
Figure 24. a+b show scanning electron microscope images  of Caco-2 cells grown for 21 days on 1 
µm SIMPLI-Well and 0.4 µm commercial polyester inserts respectively. Microvilli can be seen on 
both surfaces. c Transmission Electron Microscope image of Caco-2 cells grown for 21 days on 
1µm SIMPLI-Wells. The silicon nitride support fractured during sample preparation. The remains 
of the support are visible as dark cubic fragments, indicated by an arrow. All scale bars are 10µm 
c b a 
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4.4.5 Translocation of small molecules and polystyrene beads in the absence of cells 
To assess the barrier properties of the blank filter inserts, translocation studies with sodium 
fluorescein, propranolol and 50 nm polystyrene beads were conducted in the absence of 
cells. Apparent permeability values were calculated over a period of 20 min until sink 
conditions could no longer be maintained. Commercially available inserts with varying pore 
size were used as a reference.  
Due to the slow speed of 50nm polystyrene particle translocation across conventional 
polyester inserts, the incubation time was increased and the amount of translocated 
polystyrene beads was determined after 1, 4 and 24 hours 
The 50 nm polystyrene beads were greatly hindered in their translocation across the 
conventional polyester filter inserts. Even after 24 hours of incubation, only filters with 3 µm 
pore size reached an equilibrated state. The 0.4 µm Corning and 0.4 and 1 µm BD filters did 
not reach equilibrium after 24h. At this time they still retained more than 70% of the initial 
dose applied to the apical side.  
 
4.4.6 Translocation of small molecules and polystyrene beads in the presence of cells 
Fluorescein sodium (paracellularly transported) and propranolol (transcellularly 
transported) were translocated in the presence of fully differentiated Caco-2 cells in order to 
assess the functionality of tight junctions in the various cell culture systems.  
50 nm polystyrene beads were evaluated as a model nanoparticle formulation.  
The lipophilic propranolol with its rapid transcellular diffusion showed high permeability 
across the Caco-2 cells grown on polyester filter inserts. Transport of the more hydrophilic 
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fluorescein was statistically significantly slower (Fig. 25b). Almost no nanoparticles 
translocated to the basolateral compartment during the 4 h duration of the experiment, 
resulting in an extremely low Papp value of 10-7 cm/s. Results were comparable in ranking 
and order of magnitude for both polyester filter inserts tested (0.4 µm pore size, Corning and 
1 µm pore size,  BD).  
 
 
 
 
 
 
 
 
 
 
Significantly increased transport rates were observed for all three tested substances with 
SIMPLI-Wells. The apparent permeability of propranolol and sodium fluorescein across the 
SIMPLI-Well system was higher than across a polyester insert with the same pore size 
(Fig. 25b). However, using the 2 µm pore SIMPLI-Well, no difference between transport of 
the low permeability substance (sodium fluorescein) and the high permeability substance 
Figure 25. a) Translocation of 50 nm Fluoresbrite beads across varying pore sizes of SIMPLI-Wells and 
commercially available polyester membranes. b) Apparent permeability (Papp) values of sodium 
fluorescein, 50 nm polystyrene beads and propanolol through Caco-2 cells grown on SIMPLI-Well 
membranes and commercial polyester membranes with various pore sizes. a: highly significant 
difference P<0.001 to sodium fluorescein Papp value, b: highly significant difference to propranolol 
Papp value, c: highly significant difference to 50 nm polystyrene beads Papp value (mean ± SD, n=6). 
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(propranolol) could be observed. Utilizing 1 µm pore SIMPLI-Well, we observed that the 
system was able to discriminate between the different permeability markers giving 
approximately 5 times faster transport of propranolol compared to fluorescein sodium, the 
effect being statistically significant (p < 0.05) (Fig. 25b).  
In contrast to the polymer-based commercial systems, the SIMPLI-Well also allowed 
translocation of 50 nm polystyrene beads in the presence of the cells (Fig. 25b). Transport 
was higher for 2 µm sized pores but was still faster than the diffusion of fluorescein sodium 
for cells grown on 1 µm pore size SIMPLI-Well.  
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4.5 Discussion 
In vitro systems are needed to assess nanomaterial translocation across an epithelium, to 
screen and predict in vivo absorption of nanoparticles and nanomedicines. Testing of 
epithelial permeability is generally conducted using permeable cell culture inserts with 
porous polyester or polycarbonate filters. These systems are available from a number of 
suppliers with different filter pore sizes and insert diameters. The polyester and 
polycarbonate membranes provide excellent growth support and allow a multidirectional 
supply with nutrients, leading the epithelial cells not only to proliferate but also differentiate 
with 3D cell growth and morphology similar to that found in vivo. Furthermore, numerous 
studies of the kinetics of absorption and secretion of hydrophilic to moderately lipophilic 
small molecular compounds have been carried out. In this context the polyester and 
polycarbonate systems have been accepted as in vitro testing setup by the regulatory 
authorities and provide good in vitro and in vivo correlations. 
Permeability testing in these systems is based on the assumption that the effect of the filter 
support on the overall transport is negligible and that the limiting factor for translocation is 
the epithelial cell monolayer. As shown in equation 2, the total resistance to translocation of 
a compound (1/Pe) can be described as a series of individual resistances put in a row, where 
Pm is the permeability coefficient of the cell monolayer, Pf is the permeability coefficient of 
the filter and Pabl is the permeability of the aqueous boundary layer. 
1


1


1
	

1


              (eq 3) [153] 
              (eq 3) [153] 
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The permeability coefficient of the filter is proportional to the filter porosity (εf), aqueous 
diffusion coefficient of the molecule (D), function of the molecule size (r) to pore size ratio 
(Rf) and reciprocally proportional to membrane thickness (δf) (eq 3).  
     	 
 .   .  




    (eq 4) [153] 
 
Our studies of the transport of test compounds across a cell-free filter insert identified 
problems when nanoparticle translocation was investigated: although the filter insert should 
not present a barrier to diffusion, equilibrium in the system was not reached when using the 
commercial insert even after 24 h of incubation (Fig. 25a). Compared to small molecules the 
transport of biomacromolecules and nanoparticles across a filter is reduced due to a higher 
molecule size to pore size ratio. Increasing the pore size reduces the issue, as transport is 
faster. However, even with a 3 µm pore size no equilibrium was reached when using 
polyester inserts. Thus the issue is not only related to the larger hydrodynamic diameter but 
a large fraction of the particles seem to adsorb to the filter and clog the pores. Our results are 
in line with previous findings of Geys et al. who showed that polystyrene nanoparticles of 
46 nm size were not adequately translocated across the 0.4 µm membrane setup [154]. Only 
in 3 µm polyester filter system 50 - 70% of the total amount was translocated.  
Unfortunately, pore size cannot be increased ad libitum, as epithelial cell growth is 
dependent on the porosity parameters of the cell culture support. A bigger pore diameter 
can negatively affect cell differentiation and epithelial functionality giving cell monolayers 
with low physiological relevance. In addition, with large pore sizes, Caco-2 cells may grow 
through the porous substrate and form a second layer of cells on the basolateral side of the 
same. As a consequence, polarization of transport is lost and the model is no longer valid to 
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study active uptake and secretion processes. TEER as an indicator of barrier tightness is also 
reduced [154]. In spite of the observed not optimal conditions, in absence of easily accessible 
alternative tools, several translocation studies with Calu-3 and Caco-2 cells conducted on 
3 µm polyester filter have been reported [144, 145]. 
A number of different approaches have been taken to address this problem. Changing the 
geometry of the cell culture support to a mesh/trench allows increasing the pore size in 
Caco-2 cell culture as shown by the Gabor work group who utilized a trench construction 
with 10-20 µm width and 35 µm depth [148] but did not further characterize their system 
with regards to epithelial barrier function. Other alternative cell culture supports such as 
ThinCertTM also failed to resolve the problem, although having pore size ranging from 0.4 to 
8 µm. The overall thickness of 15 to 22.6 µm drastically reduces the permeability properties 
of the system. Another interesting approach for cell growth supports is microporous 
alumina with pore sizes from 50 to 250 nm, which has been utilized in hepatocyte 
engineering [155]. Unfortunately alumina has been shown to affect the proliferation and 
viability of cells [156] and cells grown on this surface were found to have increased distinct 
focal adhesion sites and actin stress fibers compared to cells grown on tissue culture plastics 
[155]. Another system that also addresses the permeability issue is CytoVu® from SiMPore 
Inc,. This porous support has a thickness of 100 nm to enable faster diffusion of molecules 
between the two compartments, and to allow studies of cell-cell interactions and migration. 
Available with pore sizes of 3 and 8 µm, and with an optional Nanobarrier™ addition of 50 
nm pore size, the system has been tested for the separation of molecules and nanoparticles 
[157, 158]. The system however, does not allow for TEER measurements and to the best of 
our knowledge no cell-related work has been published to date. This could be due to the fact 
that the overall surface available for cell growth is very small making the investigation of 
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translocation challenging especially if low concentrations are used.  Given the unsatisfying 
results of these systems in nanoparticle studies, a new system is clearly needed in which 
reduced thickness and/increased pore density of the cell culture support improve transport 
properties. 
 The SIMPLI-Well system was designed to fulfil these criteria. Photolithography and 
microfabrication allow the production of silicon chips with porous support areas that are 
only 500 nm thick,  enhancing permeability by a theoretical factor of 20 (Table 5). Pore size 
can be varied from 1 µm up to 3 µm as can the pore density. Studying nanoparticle 
translocation in the absence of cells in this system, equilibrium was reached within the first 
hour for both 1 µm and 2 µm pore sized porous supports. Thereby, the transport across the 
porous support itself is no longer a limiting factor when studying in vitro absorption across 
cells.  
The SIMPLI-Well has been shown to be a suitable culture support for Caco-2 cells. Fully 
differentiated and polarized Caco-2 cells developed on the silicon nitride porous supports 
with microvilli structures on the apical side (Fig. 24a&b). Cell proliferation was only 
minimally delayed: TEER, as a marker of cell proliferation and especially differentiation, 
reached a plateau after 25 days instead of 18 days in standard cell culture inserts.  On 
supports with 2 µm pores, cell nuclei and microvilli were seen on both the apical and 
basolateral compartment indicating the formation of a non-polarized double layer of cells. In 
contrast, although Fig. 24c shows that although cells were observed on both sides of a 
support with 1 µm pores, cell nuclei and functional microvilli were not seen on the 
basolateral side (data not shown). This indicates that the cell layer is polarised and suitable 
for transport studies.  
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Further tests also indicated that SIMPLI-Wells with 1 µm pores were optimal for CaCo-2 
cells. The double cell layer formed on the 2 µm SIMPLI-Wells led to higher TEER values but 
negatively affected tight junction functionality as seen in the immunostaining for ZO-1  and 
in the transport data for fluorescein and propranolol. Fluorescein sodium as a small 
hydrophilic molecule is transported by paracellular diffusion across aqueous pores in the 
tight junctions, a process which is significantly slower than the transcellular passive 
diffusion of small lipophilic molecules such as propranolol. Both compounds used in this 
study for characterizing the barrier function of Caco-2 cells are recommended by the 
regulatory authorities in the evaluation of transport models. For 2 µm SIMPLI-Wells no 
statistically significant difference between low and high permeability marker was found 
(Fig. 25b) indicating poor barrier function. In contrast Caco-2 cells grown on 1 µm pore sized 
silicon nitride supports were able to differentiate between the two compounds with a 5-6 
times higher transport of propranolol compared to fluorescein.  
Barrier function for Caco-2 cells grown on commercial polyester or polycarbonate filter 
membranes was better than on the SIMPLI-Wells, as indicated by an even larger difference 
in the transport rates of propranolol and fluorescein (Fig. 25b). However, a number of 
studies have suggested that the Caco-2 model in the commercial cell culture systems tends 
to overpredict the differences between transcellularly and paracellularly transported 
compounds [159]. The cell monolayer was deemed to have tighter tight junctions and higher 
TEER value than in in vivo values of small intestine [10]. Therefore the cells grown on 1µm 
pore sized silicon nitride membranes giving lower TEER values of 250-300 ohm*cm2 and 
significant but not overly pronounced barrier function may be closer to the actual in vivo 
situation and better simulate intestinal epithelial function.  
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A theoretical “cell permeability value” was calculated from the transport data in the absence 
and presence of cells using equation 2. In turn the relative contribution of intrinsic 
mechanical substrate resistance and cell resistance to the overall transport process could be 
calculated (Table 6). For all types of substrate and pore sizes investigated the intrinsic 
resistance of the substrate for sodium fluorescein was less than 0.2% of the total resistance. 
However, the intrinsic resistance of the substrate towards propranolol was slightly higher, 
0.6-1.4% of the total resistance. Corning 0.4 µm inserts initially presented a relatively high 
resistance to propranolol transport at 13.1% contributed resistance (data not shown). 
However, this high value may an artefact related to an unspecific binding of propranolol to 
the polyester surface in the absence of cells reducing the free concentration of propranolol 
available for transport. Indeed repeat experiments with buffer supplemented with 1% BSA 
showed increased propranolol transport across the blank polyester membrane, reducing the 
membrane resistance factor to merely 3.1%. 
 
Table 6. The percentage ratio calculated from total resistance attributed to the cells and to the filter.  
 SIMPLI-WELL 
1µm 
% Ratio 
SIMPLI-WELL 
2 µm 
% Ratio 
Corning  
0.4 µm 
% Ratio 
BD 
1µm 
% Ratio 
Sodium fluorescein 
cells 
filter 
 
99.97 
0.03 
 
99.83 
0.17 
 
99.85 
0.15 
 
99.97 
0.03 
Propranolol 
cells 
filter 
 
99.32 
0.68 
 
99.28 
0.72 
 
96.89 
3.11 
 
99.49 
0.51 
Propranolol 
cells 
filter 
 
98.78 
1.21 
 
98.98 
1.02 
 
60.73 
39.27 
 
90.99 
9.01 
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Transport experiments with fully differentiated Caco-2 cells in the SIMPLI-Well system gave 
significantly enhanced transport not only for the small molecular drugs but also for the 50 
nm nanoparticles. For nanoparticle transport, the relative resistances of both 1 µm and 2 µm 
pore sized SIMPLI-Well were very low at 1-1.2% while 1µm BD filter inserts contributed 9% 
to the total resistance and Corning 0.4µm filter inserts accounted for 39.3% of the total 
resistance to transport (Table 6). The low transport resistance of the membranes in SIMPLI 
system allows the cell monolayer to be the determining factor in translocation and transport 
study. For the first time, sufficient amount of particles were translocated through the cell 
monolayer and its membrane support to the acceptor compartment to linearly integrate 
particle translocation over a longer period of time thus allowing a calculation of valid 
permeability values. In contrast, the transport of nanoparticles is severely underestimated 
when using the commercial filter inserts and only the SIMPLI-Well allows an evaluation of 
nanoparticle/cell interactions and barrier function.  
Surprisingly, the transport rate of 50 nm polystyrene particles observed in this study was 
higher than the fluorescein transport, which may hint at a fast transcellular transport 
pathway. So far, using conventional polyester or polycarbonate-based cell culture inserts, 
nanoparticle translocation across the epithelial barriers of the body has been 
underestimated. In vitro results showing little or no nanoparticle uptake are in strong 
contrast to in vivo data showing nanoparticles to be absorbed after intragastric or 
intrapulmonary [160]. Thus, it may be necessary to revisit previous in vitro studies which 
reported negative results for nanoparticle uptake across epithelia.  
In conclusion, we found the SIMPLI-Well to be a good compromise between the need for a 
suitable mechanical support for the cells and a minimal influence on the transport process 
itself. The transport of nanoparticles was found to be significantly improved. Essentially, 
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this was achieved by reducing the thickness of the porous support from 10 µm to 0.5 µm in 
the SIMPLI-Well. This new insert system should allow, for the first time, a systematic in vitro 
screening of nanoparticles of different sizes and surface properties to determine qualitative 
and quantitative parameters predicting extent and speed of uptake across epithelia 
In this study characterizing the novel cell culture system we only focussed on 50 nm 
polystyrene latex beads as an easily detectable model nanoparticle. It remains to be seen if 
the surprisingly fast transcellular transport of the nanospheres observed here is mirrored in 
other nanomaterials. 
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5. Summary 
Inflammatory bowel disease is one of the five most prevalent gastrointestinal diseases in the 
United States and has recently increasing incidence number in developed countries and, 
along with the industrialization, also in developing countries. As incurable disease, the 
treatment for IBD are mostly includes immunosuppressant to treat the symptoms and 
prolong the remission state to increase the quality of life of the patients. 
The drugs used in the treatment are mostly highly potent and may cause severe side effects 
from nausea and vomiting to hemorrhoids and intestinal obstruction. A highly promising 
approach for better treatment and reduced side effects is the utilization of nanocarriers for 
specific drug targeting. The nanocarriers have been shown previously to have extended 
circulation time and may accumulate in the diseased area via active or passive targeting. The 
passive targeting takes advantage of one of the feature in cancer or inflamed cells, the EPR-
effect.  
Although the interest in nano research has generated huge numbers of new formulation 
strategies, there is still lack of testing tool for screening purposes. The available screening 
tools are not yet adapted to the needs in specific diseases and specific drug formulations. 
Therefore we developed the in vitro model that has the complexity and physiological state of 
inflamed colonic mucosa for the testing of specific drug and its formulations.  
The inflamed model of colonic mucosa described in this thesis showed that in vitro models 
are not out of date and can be developed to a more complex system, reaching a better 
approximation of in vivo condition. Although simple with only three cell components, the in 
vitro model enables characterization of each of its component and therefore builds a tightly 
controlled microenvironment of diseased tissues. The development of the model has 
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revealed the stimulation by LPS was able to increase the cytokine level, but not to disrupt 
the barrier function. IL-1ß in the other hand was able to reduce the TEER value and to 
inflame the model reversibly. The addition of immune cells as expected also enhances the 
immune response in the model and also allows the first insight in the mechanistic study of 
particle uptake. The resulting inflamed model were found to have similar characteristics as 
inflamed tissue, having increased pro-inflammatory cytokine level, reduced TEER value and 
increased mucus production. The inflammation state retained for about 5 days, giving 
sufficient timeframe for drug testing. 
The first drug formulations tested in the system were of budesonide encapsulation. This 
drug is a well known potent drug for IBD, though still has low availability in the site of 
action due to its hydrophobic properties. PLGA nanoparticles and liposomes were designed 
to encapsulated budesonide and the efficacy in the treatment was evaluated by the inflamed 
model of colonic mucosa. 
The results from the evaluation showed that the PLGA nanoparticles are suitable for IBD 
treatment as they seemed to be accumulated in the leaky area of epithelial barrier and acted 
as a depot that may release the budesonide slowly over the time, as hinted by the extended 
low inflammation level of the model treated with this formulation. Liposomal budesonide in 
our study worsen the inflammation state of the model, presumably due to its toxicity. We 
speculate that the liposomes were taken up by the immune cells compound in the model 
and get a peak in immune response over the threshold to the level of high toxicity to the 
epithelial cells.  The problem may be solved by modulating the concentration of budesonide 
and liposome used to reach the optimal formulation concentration without toxicity to be 
used in further animal study. 
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In our approach of developing the in vitro model for drug evaluation we have previously not 
addressed a very important factor: the study of nanocarriers transport across the epithelial 
barrier. With all the advantages, the developed model is not suitable for the transport study 
due to the collagen layer in the model, and most importantly due to the filter support used 
in the model being thick and small in pore size. As part of the project we tried to overcome 
this issue by testing a novel silicon nitride membrane support system with increased pore 
size and number as well as reduced membrane thickness. The resulting membranes are 
biocompatible and robust for cell culture handling. One of the vital factors in drug 
permeability study is the monolayer state of the cells, simulating the monolayer in epithelial 
or endothelial barrier. This novel membrane system has small enough pore size to not allow 
the cells to slip through the membrane and form a double layer beneath the membrane, but 
big enough for nanocarrier translocation.  The cells grown on the membrane filters were 
shown to have characteristics of differentiated monolayer, with increased TEER value and 
microvilli formation. With differentiated monolayer grown on the alternative silicon support 
membrane, the transport properties were significantly increased in most of the substance 
tested, especially for nanoparticles, when previously only very low detectable amount was 
found to be transported in the conventional Transwell filter system. The cells grown on 
these membranes were also able to discriminate different compounds transported 
paracellularly or transcellularly. To our best knowledge, this is the first study to report the 
suitable transport study set up for nanoparticles tested for intestinal absorption study.  
In conclusion, we have successfully developed a working in vitro model for inlamed colonic 
condition which can be utilized for drug and formulation testing. Although with its 
limitation, the model can predict the drug formulation efficacy, length of action and 
accumulation in inflamed tissue. The novel silicon membrane system developed in this 
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study has been proven as a useful and promising tool for nanoparticles transport study. The 
membrane support may as well be combined with the in vitro model in the future to 
overcome the transport limitation of the model. The thinness of the silicon membrane may 
enable the model without collagen layer and immune cell seeding on the basolateral side, 
allowing a close contact to the epithelial cells on the apical side of the system. 
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6. Outlook 
The in vitro model of inflamed mucosa, although was developed as inflammatory model, has 
potential to be utilized for other applications. Well equipped for evaluation of inflammatory 
response, the non-inflamed model can be used to test various food allergens and food 
toxicity. The main critic, which could also be one of the main advantages of this model, is the 
simplicity of the model. By including only the three cell types important to the immune 
response with a certain ratio of cells, the controlling over the three variables are easier than 
in vivo condition. This enables the tight control over the parameters and monitoring of their 
changes upon the drug formulation testing, delivering the mechanistic information of drug 
formulation and their effects in the intestinal barrier. Although very superior in mimicking 
the inflammation, the model still missed some important factors and may be enhanced in the 
future direction to improve the prediction for clinical success, depending on its application. 
In UC, the mucus thickness was found to be decreased compared to healthy tissueand 
therefore our in vitro model gives very close approximation to the in vivo condition. 
However, the mucus barrier has been reported to be increased in CD. Therefore the addition 
of mucus layer, by adding the mucus producing goblet cells for example, is important to 
simulate the additional barrier for drug delivery and to study the adhesion of drug 
formulations in the healthy or CD-affected intestine. The culture length of 21 days before 
maturation, although necessary for enterocytes differentiation, might have influence the 
phenotype and viability of the primary immune cells. Primary macrophages and dendritic 
cells, being isolated directly from human blood, have the variability of immune response 
and viability of each isolation. Another approach for standardization of the inflamed model 
is to incorporate stimulated monocytic cell lines to replace the primary immune cells.  
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Another valid point that was not addressed in this model is the flow condition in the 
intestine. The shear stress of the flow may affect drug formulation adhesion and 
accumulation in the lumen. Addition of flow in the model will add more accurate prediction 
of drug accumulation and absorption in non-static condition.  
So far we have used conventional filter membrane system to simulate the dual compartment 
in in vivo intestinal tissue. The thickness of the membrane did not allow the cells on the 
basolateral compartment of the membrane to interact freely with the cells on the apical side, 
and therefore the immune cells were added in the same compartment in the inflamed 
colonic mucosa model. Our findings with the silicon nitride membrane revealed that the 
membranes are much thinner and not only give better transport properties to the cells 
grown on the membranes, but also will allows cells from both compartments to interact 
directly. Thus, the novel SIMPLI-Well can be utilized to improve the in vitro model. 
Addition of immune cells can be conducted after the maturation of epithelial monolayer, 
therefore increasing the viability and inflammatory potential. This will also adding the value 
of the model for transport study of drug formulations by removing the collagen component, 
which hinder the transport study in the previous model. 
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8. Abbreviations 
ADME absorption, distribution, metabolism, and excretion 
  
ANOVA analysis of variance 
  
API active pharmaceutical ingredient 
  
BCRP breast cancer resistance protein 
  
BCS Biopharmaceutical Classification System 
  
CBA Cytometric Bead Array 
  
CD Crohn’s disease 
  
cDNA Complimentary Deoxyribonecleotide acid 
  
CFU Colony-forming  unit 
  
CLSM Confocal Laser Scanning Microscopy 
  
CYP3A4 Cytochrome P450 3A 
  
DC dendritic cells 
  
DMEM Dulbecco's modiﬁed Eagle's medium 
  
DPPC Dipalmitoyl Phosphatidylcholine 
  
DSPE Distearoyl-Phosphatidylethanolamine 
  
DSS dextran sulfate sodium 
  
EDTA ethylenediaminetetraacetic acid 
  
EPR Enhanced Permeability and Retention 
  
FACS Fluorescence-activated cell sorting 
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FCS Fetal Calf Serum 
  
FDA Food and Drug Administration 
  
FITC fluorescein isothiocyanate 
  
FluNa fluorescein sodium salt 
  
GM-CSF granulocyte-macrophage colony-stimulating factor 
  
HPLC high-performance liquid chromatography  
  
IBD Inflammatory bowel disease 
  
IFN-γ interferon gamma 
  
I-κB inhibitor of κB 
  
IL-x Interleukin 
  
KRB Krebs ringer buffer 
  
LPCVD low-pressure chemical vapor deposition 
  
LPS Lipopolysaccharide 
  
MLCK myosin light-chain kinase  
  
MRP multidrug resistance associated protein 
  
NF- κB nuclear factor kappa-light-chain-enhancer of activated B cells 
  
NOD2 nucleotide-binding oligomerization domain-containing protein 2  
  
Papp apparent permeability 
  
PBMC peripheral blood mononuclear cell  
  
PBS phosphate buffered saline 
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PCR polymerase chain reaction  
  
PEEK Polyether ether ketone 
  
PepT1 peptide transporter 1 
  
PLGA poly(lactic-co-glycolic acid) 
  
PMA Phorbol 12-myristate 13-acetate 
  
PVA Polyvinyl alcohol 
  
RIE reactive-ion etching 
  
RNA ribonucleic acid 
  
R-PE R – Phycoerythrin 
  
RPMI Roswell Park Memorial Institute medium 
  
SIMPLI Silicon Microporous PermeabLe Insert 
  
TEER transepithelial electrical resistance 
  
TNBS trinitrobenzene sulfonate 
  
TNF-α Tumor Necrosis Factor alpha 
  
TLRx Toll-like receptor 
  
UC Ulcerative colitis 
  
ZO-1 Zona occludens-1 
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